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A quiralidade é a uma propriedade importante na indústria farmacêutica, uma 
vez que um enantiómero de um fármaco pode exercer o efeito terapêutico 
desejado enquanto o outro pode ser inerte ou mesmo nefasto. Embora vários 
fármacos sejam comercializados na sua forma racémica, as entidades 
regulatórias aconselham o desenvolvimento de fármacos enantiomericamente 
puros e mais seguros. Neste contexto, a indústria farmacêutica procura formas 
baratas e eficientes de produzir fármacos enantiomericamente puros, sendo 
este o objetivo da presente tese. 
A separação enantiomérica do ácido mandélico (AM), aqui utilizado como um 
fármaco racémico modelo, será tentada recorrendo a sistemas aquosos 
bifásicos (SABs) constituídos por seletores quirais de origem natural (proteínas 
e açúcares). Serão usadas duas abordagens: (i) a introdução de proteínas 
como seletores quirais em diferentes tipos de SABs; e (ii) o uso de (D)-sacarose 
simultaneamente como seletor quiral e componente de fase em SABs. Na 
primeira abordagem, foram utilizados diferentes tipos de SABs 
(polímero+polímero, polímero+sal, sal+líquido iónico (LI), polímero+LI e 
polímero+açúcar) e duas proteínas (albumina de soro bovino – BSA – e 
citocromo C – Cit c). A escolha das proteínas assentou em resultados de 
molecular docking que indicaram interações distintas entre diferentes proteínas 
e os enantiómeros do AM. Nestas fases, os sistemas constituídos por 
PPG400+(D)-Sacarose+BSA (excesso enantiómerico de -5.9± 0.5%) e 
PPG400+dihidrogeno fosfato de colínio+Cit c (excesso enantiomérico de -9.0 ± 
1.2%) revelaram-se os mais eficientes. As proteínas e os constituintes de fase 
dos SABs afetaram a separação enantiomérica de ácido mandélico. Uma vez 
que a docagem molecular não considera as interações com os componentes de 
fase, esta abordagem revelou ser incapaz de prever o desempenho das 
proteínas como seletores quirais em SABs. 
Com o objetivo de ultrapassar as limitações de seletividade enantiomérica e 
melhorar a simplicidade operacional da tecnologia proposta, a (D)-sacarose foi 
usada simultaneamente como formador de fase e seletor quiral em SABs. 
Depois de uma otimização cuidada, foi possível obter um excesso 
enantiomérico máximo de -12.3 ± 0.5% com um SAB constituído por polímero e 
(D)-sacarose. 
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abstract 
 
Chirality is an important property for the pharmaceutical industry, since one 
enantiomer of a drug can exert a therapeutic action, while the other may be 
inert or even nefarious. While several drugs are commercialized as racemates, 
regulatory bodies strongly encourage the development of safer enantiopure 
drugs. In this context, pharmaceutical industry seeks for cheap and efficient 
ways of obtaining enantiopure pharmaceuticals and this is the main objective of 
this thesis.  
The enantiomeric separation of mandelic acid (MA), here used as a model 
racemic drug, using aqueous biphasic systems (ABS) composed of natural 
chiral selectors (proteins and sugars) will be proposed. Two different 
approaches were used: (i) the introduction of proteins as chiral selectors in 
several types of ABS; and (ii) ABS formed by D-Sucrose as both phase former 
and chiral selector. Within the first approach, different types of systems 
(polymer+polymer, polymer+salt, polymer+sugar, and ionic liquids (ILs)+salt, 
ILs+polymer) and of proteins (bovine serum albumin –BSA - and cytochrome C 
– Cyt C) were used. These two proteins were chosen based on molecular 
docking results that shown distinctive interactions with the two MA enantiomers 
among eleven screened proteins. PPG400+(D)-sucrose+BSA system 
(enantiomeric excess of -5.9 ± 0.5%) and PPG+cholinium 
dihydrogenphosphate+Cyt C (enantiomeric excess of -9.0 ± 1.2% were the 
most efficient ABS developed up to this stage. Both the protein and ABS phase 
formers affected the enantioseparation of MA. Since molecular docking does 
not encompass the interactions with the ABS phase formers, it was limited at 
predicting the proteins’ performance as chiral selectors in ABS. 
In order to surpass the limited enantioselectivity displayed and to improve the 
operational simplicity of the proposed technology, (D)-sucrose was employed 
as both chiral selector and phase former in ABS. After a proper optimization, it 
was possible to achieve a maximum enantiomeric excess of -12.3 ± 0.5% with 
an ABS composed of polymer and (D)-sucrose. 
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Chirality is a property of a molecule that is non-superimposable with its mirror 
image, each image being an enantiomer, as it happens with the mirror images of human 
hands – Figure 1. [1] Chirality is a crucial property that nature uses to perform its 
functions, such as protein folding, DNA double helix, phospholipid membranes and 
photosystems.[2] 
 
 
Figure 1 - Enantiomers of mandelic acid as a representative example of chirality with the analogy to 
human hands. 
 
Stereoisomers are molecules that have an identical atomic constitution and 
bonding,[3] but differ in the three-dimensional arrangement of their atoms. Despite 
having the same chemical structure and physical properties (in most cases excepting for 
optical activity), a pair of enantiomers may induce very different effects in living 
systems. Differences at the level of pharmacological, toxicological, metabolic, among 
other biological activities, may occur. Hence, chirality occupies an important role in 
many fields, such as in agrochemical industry,[4] food safety,[5] and, especially, 
pharmaceutical industry.[6] Here, an enantiomer may cause the desired therapeutic 
effect (eutomer), and the other (distomer) may be less potent, bio-inert or even 
toxic.[7,8] Active pharmaceutical ingredients like the non-steroidal anti-inflammatory 
drug ibuprofen and the anticoagulant agent warfarin have their enantiomers with the 
same activity and are taken as racemates in a safe way. Other racemic drugs have one of 
the enantiomers that causes harmful side effects.[9] The most popular case occurred in 
the 1950s, when the immunomodulatory agent thalidomide was prescribed for 
insomnia’ and cutaneous diseases’ treatment,[10] as a sedative, and mainly to heal 
nausea in pregnant women.[11] While this drug was being marketed as a racemate, the 
unknown teratogenic action of the S enantiomer caused anomalies in children, such 
congenital heart diseases, malformations in the members and ocular abnormalities.[12] 
Other example is methadone which is used to treat chronic pain,[13] but the S 
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enantiomer is linked to cardiac arrhythmia due to its interaction with the human Ether-à-
go-go Related Gene (hERG) channels in cardiac myocites. In addition, Parkinsons’ 
disease symptoms are treated with levodopa, however the enantiomer D causes 
granulocytopenia. In this context, regulatory entities perform a tight control of the 
medicines going to be commercialized.[9,14] Although the use of enantiopure drugs is 
preferred, if the racemic form is wanted by the industry, the supply of the detailed 
pharmacologic, pharmacokinetic and toxicological data for each enantiomer and 
respective racemate is mandatory. This calls the attention for the development of 
efficient approaches to obtain pure enantiomers.[15] 
In this context, this work intends to develop an alternative method for chiral 
resolution. For that purpose, aqueous biphasic systems (ABS) with proteins acting as 
chiral selectors will be studied. This alternative process is intended to become an easy, 
flexible, and environmentally friendly alternative to the techniques used today. 
1.1. Available approaches to produce pure enantiomers 
Two distinct approaches are used to obtain enantiopure compounds, as shown in 
Figure 2, namely (i) the chiral approach in which the synthesis of the desired 
enantiomeric molecule is focused, and (ii) the racemic approach describing the 
separation of enantiomers of a racemic mixture.[16] 
 
Figure 2 - Summary of different methods used to produce enantiopure compounds. (Adapted from [1]) 
 
The chiral approach (or asymmetric synthesis) consists on the enantioselective 
conversion of an achiral molecule into a chiral one or on the diastereoseletive 
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conversion of a chiral molecule into other chiral compound. [17] This is the preferred 
and most robust approach to produce enantiopure compounds and it covers four main 
different methods according to Figure 2. Asymmetric catalysis is based on small 
amounts of enantiopure catalysts that can promote desired reactions and lead to the 
formation of large amounts of enantiopure products.[18] Biocatalysts,[19] metal-ligand 
complexes derived from chiral ligands[20] and chiral organocatalysts[21] are the chiral 
catalysts most employed. Chiral auxiliaries are organic compounds that bond to the 
starting material to form diastereomic species by enantioselective reactions.[22] The 
formation of these species implies an energetic difference between them, allowing their 
enantiodiscrimination. Chiral building blocks for synthesis of enantiopure molecules 
can also be employed, as shown by Magdziak and collaborators.[23] The chiral starting 
materials are transformed into the desired enantiopure compound by multiple and 
consecutive reactions; this is the least complicated way. Finally, the selective natural 
metabolism of microorganisms may also be used to produce optically pure compounds 
via fermentation as done already at industrial scale to obtain enantiopure amino 
acids.[24] In general, the methods of the chiral approach are highly efficient, but require 
large stoichiometric amounts of enantiopure raw material and usually need numerous, 
time consuming and laborious reactions, being expensive and complex to operate. 
The racemic approach (or enantioseparation) appears as simpler and more flexible 
candidate to substitute the asymmetric synthesis.[25] An initial asymmetry is usually 
needed for enantioseparation, often by the introduction of specific chiral partners, such 
as reactants, solvents, carriers or solid surfaces.[26] Enantioseparation can be easily 
achieved with at least one of the commercially available chiral selectors. Many chiral 
selectors exist and can be obtained from natural sources or from synthetic routes,[27] as 
shown in Figure 3. Due to their diversity, the identification of good chiral selectors for a 
specific racemate is usually time consuming and laborious. 
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Figure 3 - Summary of the most used chiral selectors organized according to their origin. (Adapted from 
[28]). 
 
The key in chiral recognition is the formation of diastereoisomeric complexes 
between the enantiomers and the chiral selector. Molecular recognition occurs because 
of the differences in the Gibbs free energy between the two diastereoisomeric 
“enantiomer–chiral selector” complexes. Easson and Stedman[29] proposed that a 
minimum of three points of attachment is needed for chiral recognition, as shown in 
Figure 4. Thus, the key for the three-point interaction model is that at least three 
simultaneous interactions occur with three different substituents attached to the 
stereogenic center.[30] Two different interactions with the same substituent increase the 
chiral selector–ligand binding energy and has no effect on the chiral recognition 
efficiency. It should be noted that three simultaneous interactions are not always 
required,[31] namely in the case chiral selectors have π-complexes and use aromatic 
associations that discriminate between two similarly rigid chiral molecules (i.e. pseudo-
two point interaction model). There are different intermolecular forces that may be 
taking place between two enantiomers and the chiral selector, namely hydrogen 
bonding, steric hindrance, π-π stacking, ion-dipole, dipole-dipole, dipole-induced-
dipole, van der Waals and electrostatic interactions.[32]  
 
Figure 4 - Graphical representation of the “Three Point Interaction Model”. (Adapted from [32]). 
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The main enantioseparation methods used today are crystallization, 
chromatography, kinetic and dynamic kinetic resolution and enantioselective liquid-
liquid extraction (ELLE) – Figure 2. Since Pasteur’s discovery on the crystallization of 
two enantiomers of sodium ammonium tartrate,[33] crystallization is one of the 
techniques most adopted by industry. Two major types of enantioselective 
crystallization exist, namely the commonly designed as classical resolution, where the 
target racemate is transformed into two diastereomeric salts of distinct solubility by an 
enantiopure resolving agent, and the preferential crystallization of conglomerates. 
Despite being easily applicable after other enantioseparation techniques, simple to 
operate and cost-efficient, crystallization is only an option for few chiral compounds, 
needs an excessive handling of solids and normally is recognized for its low yields (of 
around 50%).[34] 
The kinetic resolution is a process based on the difference of consumption rates of 
the two enantiomers in an enantioselective reaction in presence of a chiral catalyst or 
reagent. From this process results an enantio-enriched sample of less reactive 
enantiomer.[35] There is a variation of this method called dynamic kinetic resolution, 
where it is possible to convert the achiral reactant with 100% completion because both 
enantiomers are in equilibrium.[36] Nevertheless, the absence of suitable reaction 
partners and the typically high purity standards required for the product limits its 
application.  
Membrane-based enantioselective processes are divided into two main types. One 
uses a non-enantioselective membrane that assists in an enantioselective process,[37] 
and the other has enantioselective chiral membranes directly performing the 
separation.[38] Membrane-aided techniques consist on attractive candidates to enhance 
the greenness, energy efficiency, easiness and continuous mode operation of the 
enantioseparation processes.[39] However, there is a need for several operational stages 
to reach high purities, the relatively low transport rates of the membranes, the risk of 
membrane fouling or loss of stability for long operation times.[37] 
Enantioselective chromatography is not only an useful analytical tool, [40] but also 
a preparative technique to obtain pure enantiomers from a large diversity of 
racemates.[41] For enantioseparation, high performance liquid chromatography (HPLC) 
[42] can be performed using chiral mobile phases or chiral stationary phases (CSP).[43] 
With this, chromatographic techniques became more reliable, flexible, quick and 
efficient,[44] delivering both enantiomers with a high optical purity. However, 
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chromatographic techniques are limited by high losses of the product and limited 
scalability.[40] 
ELLE appears as a more appropriate solution for large scale applications. 
Conventionally, ELLE combines the concepts of enantiomeric recognition based on the 
three-point model and solvent extraction using water-immiscible volatile organic 
solvents.[46,47] The introduction of one chiral selector (e.g. derivatives of crown ether, 
tartaric acid, cyclodextrin, amino acids, metallic complexes) and its partition between 
the two immiscible phases will control the enantioseparation,[47] as shown in Figure 5. 
Monophasic chiral recognition was used by Ren et al. [48] The authors proposed the use 
of L-tartaric acid esters as chiral selectors in the organic phase of an ELLE system for 
the enantioseparation of racemic ibuprofen. The first step of that work was the study of 
the chiral recognition mechanism using the density functional theory (DFT). Two 
carbonyl and two ether groups exist in the L-tartaric acid dihexyl ester and ibuprofen 
has one carboxyl group, all able to form hydrogen bonds for chiral recognition 
interactions. Moreover, the two hexyl chains present in the L-tartaric acid dihexyl ester 
structure and the phenyl group existing in the ibuprofen can induce a steric hindrance, 
which discriminates between the two ibuprofen enantiomers. Both R-ibuprofen and S-
ibuprofen can form complexes with L-tartaric acid dihexyl ester because both 
complexes have negative binding energies, with stronger interaction with R-ibuprofen. 
The results show that O−H···O interactions are less than 3.0 Å of distance and greater 
than 0° of angle, indicating that the chiral recognition mainly involves hydrogen-
bonding interactions. The “R-ibuprofen-L-tartaric acid dihexyl ester” complex is more 
stable, because it has a number of hydrogen bonds 2-fold higher than in the “S-
ibuprofen-L-tartaric acid dihexyl ester” complex. Moreover, biphasic recognition 
appears in ELLE for better enantioselectivities. That is, the use of two distinct chiral 
selectors that will be located in opposite phases of the ELLE system. In theory, this is a 
better alternative since chiral selectors and “chiral selector-enantiomers” complex will 
be only soluble in one of the phases. An ELLE system formed by D-diisopropyl tartrate 
(DIPT, hydrophobic chiral selector) in the organic phase and hydroxypropyl-β-
cyclodextrin (HP-β-CD, hydrophilic chiral selector) in the aqueous phase was employed 
to separate racemic amlodipine. DIPT has a preference to R-amlodipine, thus 
concentrating the molecule in the organic phase. The S-enantiomer was recognized by 
HP-β-CD, forming a complex in the aqueous phase. A total separation of amlodipine 
enantiomers occurs by their partition to opposite phases.[49] Finally, reactive 
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enantioseparation in ELLE was suggested by Huang et al.[50], who showed that it is 
possible to use a chiral ketone as chiral extractant with Aliquat 336 to separate amino 
acid racemates. Ketone (S)-3, synthetized from (S)-1,1´- bi – 2- naphtol (BINOL) – 3-
carboxil, shows high kinetic enantioselectivity for L-amino acids with hydrophobic 
substituents and a high thermodynamic enantioselectivity for D-amino acids with polar 
side chains. Reversible ketamine formation and hydrolysis are essential for 
enantioselectivity for L-amino acids in this process. Gong and Xu[51] tried kinetic 
resolution of racemic mixtures coupled to ELLE using whole cells of Bacillus 
megaterium ECU1001 of chiral epoxides. It was used an isooctane+aqueous biphasic 
system to overcome the poor solubility of glycidyl phenyl ether (GPE) in the aqueous 
phase, resulting in a significant improvement of the enantiomeric ratio from 39.5 to 
94.0. In the end, it was possible to obtain (S)-GPE with 100% of enantiomeric excess 
and a yield of 44.5%.  
Automatized and continuous operation in countercurrent are easily adapted to ELLE 
keeping high recoveries and low energy consumption.[48,53] Despite these advantages, 
the use of large amounts volatile organic solvents makes it not recommendable from an 
environmental point of view.  
 
 
Figure 5 - Schematic representation of enantioseparation with ELLE systems. ▲corresponds to R 
enantiomer,♦ to S enantiomer and ◊ to a chiral selector specific to S enantiomer. Adapted from [32]. 
1.1.1. Aqueous biphasic systems 
In the last 50 years, aqueous biphasic systems (ABS) appeared as an alternative for 
the traditional ELLE based on volatile organic solvents.[53] This method is considered 
more attractive due to its high water content. This improves the biocompatibility and 
environmental impact of the separation and purification processes.[54] The formation of 
ABS appears from mixing pairs of incompatible and water soluble solutes together in 
aqueous solution, and above certain concentrations. Knowing the phase diagram (Figure 
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6), where the biphasic and monophasic regions are respectively located above and 
below the binodal curve, it is possible to determine the amount of each solute needed to 
have a biphasic system. 
 
 
Figure 6 - Representation of a theoretical ABS with the binodal curve represented in blue and the biphasic 
mixture point in yellow. 
 
The most common combinations are polymer-polymer,[56,57] polymer-salt,[58, 59] 
or salt-salt,[60,61] but others such as alcohol-salt, [62,63] acetonitrile-carbohydrate, 
[64,65] polymer-carbohydrate,[65] polymer-amino acid,[66] ionic liquid (IL)-
polymer,[68,69] IL-carbohydrate,[70,71] IL-amino acids [72,73], surfactant-amino 
acids,[73] have appeared recently. Hence, in addition to enhanced biocompatibility, 
these systems are versatile, because a wide range of phase formers can be used to 
prepare ABS for any desired application.[75,76] ABS were introduced for chiral 
resolution purposes by Sellergren and Ekberg in 1985.[76] The authors proposed an 
ABS formed by two polymers with bovine serum albumin (BSA) as the chiral selector 
to resolve tryptophan racemates. Nowadays, besides polymer-polymer 
combinations[76]–[78] others exist, like polymer-salt,[80–82] polar organic solvent-
salt,[83,84] polar organic solvent-oligosaccharide,[85,86] and IL-salt.[86] 
There are two main modes to apply chiral ABS. One uses a chiral selector which is 
not essential for the ABS formation [79]–[81,83,84] and the other uses one of the 
solutes simultaneously as chiral selector and phase former.[78,85,86] In terms of chiral 
molecules studies, drugs (mandelic acid [81] and its derivatives,[79] non-steroidal anti-
inflammatory drugs,[87] antibiotics,[79,89]) and amino acids (tryptophan [83] and 
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phenylalanine[87,90]) are the most common. A summary of the most used ABS and 
main chiral selectors used is given in Figure 7. 
 
 
Figure 7- Summary of the types of ABS reported in literature as useful for chiral resolution. 
 
The parameters used to evaluate the enantioselectivity in ABS are the 
enantioselectivity (α) and the enantiomeric excess (e.e.). Enantioselectivity (α) is the 
ratio between the partition coefficients of each enantiomer (KS and KR) indicating that 
for α > 1 an ABS presents enantioselectivity. The enantiomeric excess (e.e.) measures 
the level at which one ABS phase is more enriched in a single enantiomer, meaning that 
a 50:50 constitution represents an e.e. of 0%, while a phase containing a single 
enantiomer has an e.e. of 100%. 
The selectivity results obtained up to now with chiral ABS are very promising. The 
first approach was able to reach circa of 58% of e.e. for R-phenylsuccinic acid when an 
ethanol+salt ABS with two chiral selectors (L-(+)-tartaric acid diisopropyl ester and 
hydroxypropyl-β-cyclodextrin) was used. [90] In a surfactant-based system, with Cu2-β-
CD acting as the chiral selector, it was possible to resolve mandelic acid racemates with 
an e.e. of circa 68%. [91] This type of micellar systems was the most efficient at 
resolving mandelic acid racemates in literature. Mandelic acid and its derivatives (α-
cyclohexylmandelic) were also resolved using IL+salt ABS + HP-β-CD,[92] 
polymer+salt ABS + Cu2-β-CD[79] and alcohol+salt ABS + sulfonated β-CD (with 
different degrees of substitution).[93] In the work of Ni et al.[94], microbial cells are 
used as chiral selectors in ABS formed by polyethylene glycol with 400 g mol-1 of 
molecular weight (PEG 400) and Na2HPO4. (S)-(4-Chlorophenyl)-(pyridin-2-yl) 
methanol, an important intermediate of anti-allergic drug beta histidine, was separated 
by accumulating substrate/product in the polymer-rich phase. The substrate tolerance 
and biocompatibility of microbial cells were improved in ABS. 
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With the second approach, even if simpler technologies are created (no need for an 
additional chiral selector), the enantioseparation is in general more limited. For instance, 
chiral polymer+polymer systems obtained a separation factor of 1.27 for mandelic acid. 
Values 1.5 to 2 fold higher were achieved with organic solvents and oligosaccharides as 
the chiral phase former for racemic phenylsuccinic acid[85] and zopiclone[84], 
respectively. Finally, very promising systems were created with combinations of chiral 
ILs+salts with the addition of copper acetate. Racemic phenylalanine was separated 
with enantiomeric excesses between 53 – 65%.[87,90] With chiral ILs formed by 
tropine chiral cation and L-proline chiral anion, the separation was based on the three-
point model involving interactions between the anion L-proline, the cation tropine, and 
D-phenylalanine with copper ion.[89] NMR and DFT measurements were carried to 
support this hypothesis. 
 
1.2. Proteins as chiral selectors  
Proteins are constituted by amino acids, which normally are L-isomers, that could 
be used as natural chiral selectors in several enantioseparation processes.[95] They are 
an obvious choice as chiral selectors, because they can discriminate a wide range of 
chiral drugs (charged or neutral). However, difficulties occur from their high 
susceptibility to small changes in the medium conditions, mainly of pH, ionic strength 
and solvents type and amount, inhibiting the enantiomeric recognition. Moreover, it is 
not easy to describe a simple mechanism for enantiomeric recognition with proteins, 
because they contain multiple binding sites. All type of interactions, as discussed 
before, can occur between the target enantiomer and proteins.  
Matsunaga[96], for instance, modified the Tryptophan (Trp) 26, the only Trp 
residue, in chicken 1-acid glycoprotein (1-AGP), with 2-nitrophenylsulfenyl chloride 
and compared their application for chromatographic columns for the chiral separation of 
neutral, acidic and basic compounds. Without Trp26, 1-AGP lost its chiral recognition 
ability for propranolol, alprenolol and oxprenolol and had decreased its 
enantioselectivity for chlorpheniramine, ketoprofen and benzoin. These results suggest 
that this protein has a better recognition with Trp26 residue, suggesting that this is 
responsible for the chiral recognition mechanisms involved. Warfarin binds to the 
subdomain IIA of Human serum albumin (HSA) and both R- and S-enantiomers bind in 
identical conformations and geometric arrangement.[97] In HSA-coumarin complex 
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formation, coumarin’s benzyl-moieties have no role in the HSA chiral recognition. The 
main difference in coumarin enantiomers is in the acetonyl group conformation and in 
the different hydrogen bonding occurring between Arginine (Arg) 222 residue and the 
carbonyl of the coumarin ring (in the R-complex) and of the acetonide (in the S-
complex).[98] The binding to HSA is similar for both enantiomers, which suggests a 
low degree of enantioselectivity for warfarin enantiomers. Meanwhile, the 
stereoisomers quinine and quinidine bind differently to BSA as revealed by Liu et 
al.[99] using spectroscopic techniques. BSA has a higher affinity for quinine than for 
quinidine.[100] The aromatic groups present in these alkaloids as well as the higher 
proximity to Trp and tyrosine (Tyr) residues of quinine were shown to dictate the 
enantiomeric recognition.[100,101] 
These enantiomeric recognition mechanisms are useful for the development of 
successful enantioseparation techniques. BSA and HSA are the most commonly used 
proteins as chiral selectors. The most common techniques using proteins as chiral 
selectors are HPLC and capillary electrophoresis (CE), as shown in Table 1. However, 
other techniques were studied, using hemoglobin in electrochemiluminescence [101], or 
even antibodies in bionanotube membranes.[102] 
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Table 1 - Some examples of proteins as chiral selectors used in different enantioseparation methods. 
Protein Enantiomers Enantioseparation method  Ref. 
BSA Propanol, ofloxacin, verapamil CE [103] 
 Tryptophan derivates CE [104] 
 Tryptophan Membranes [105] 
 Propanol, Tryptophan CE [106] 
 Profen HPLC [107] 
 Penicillamine Electrochemical methods [108] 
 Tryptophan Counter-current chromatography [109] 
 Tryptophan, Hydrobenzoin, Phenylalanine, Mandelic acid HPLC [110] 
 Propanolol Electrochemical sensing layer [111] 
 Ibuprofen, ofloxacin HPLC [112] 
 Tryptophan Ultrafiltration/Membrane [113] 
HSA D,L-dansyl aminoacids HPLC [114] 
 Cetirizine HPLC [115] 
 Tryptophan Affinity ultrafiltration [116] 
 Propanol, ofloxacin, verapamil CE [103] 
AGP R,S-propanol HPLC [117] 
Trypsin Amino acids HPLC [118] 
Pepsin 
Trimipramine, propranolol, promethazine, verapamil, cloperastine, 
oxprenolol, pindolol 
Capillary electrophoresis [119] 
Casein DNP-amino acids Capillary electrophoresis [120] 
Lysozyme Tryptophan, dansyl-leucine, PTH-aspartatic acid 
Tubular capillary 
electrochromatography 
[121] 
Hemoglobin Penicillamine Electrochemioluminescence [101] 
Antibody 4-[3-(4-fluorophenyl)-2-hydroxy-1-[1,2,4]triazol-1-yl-propyl]-benzonitrile Bionanotubes membranes [102] 
Ovoglycoprotein Eparipsome, tolperisome, chlorpheniramine, verapamil CE [122] 
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1.2.1. Aqueous biphasic systems containing proteins as chiral selectors 
Proteins have been employed in chiral ABS for enantioseparation since 1985.[123] 
With the advances on ABS application for protein separation, it is nowadays known that 
these systems can maintain the protein structure, stability and activity if well 
designed.[55,125] It is also known that proteins interact with the surrounding molecules 
present in an ABS phase, mainly by hydrogen bonding, electrostatic interactions, π-π 
stacking and hydrophobic interactions. Thus, salting-out and the hydrophobicity are the 
main phenomena justifying the protein extraction in ABS. By judicious choice of the 
phase formers it is possible to concentrate the protein into a single phase.[74] The 
maintenance of proteins’ structure, stability and activity and their concentration into one 
phase make ABS containing proteins as good candidates for enantioseparation 
processes.  
Arai et al. [78] used BSA and ovomucoid as chiral discriminator in an ABS formed 
by dextran 40 and PEG. Ofloxacin enantiomer was recognized by BSA with an e.e. of 
62%, but the enantiomers of carvedilol (b-blocker) and DG-5128 (a new oral 
hypoglycemic drug) were poorly recognized by ovomucoid. It was possible to obtain a 
R-ofloxacin enriched sample by purification by thin-layer chromatography. In the work 
of Shinomiya et al.[80], BSA was used as chiral discriminator to separate enantiomers 
of kynurenine in an ABS constituted by PEG 8000 and Na2HPO4. BSA was 
concentrated in the polymer-rich phase. The separation was done with a high-speed 
countercurrent chromatography, where the lower Na2HPO4-rich mobile phase eluted the 
L- kynurenine prior to the D-isomer, with a peak resolution of 0.94.[123] This 
demonstrated the affinity of BSA to the D-isomer, since the L-isomer was eluted in the 
salt phase and the BSA would be present in the polymer-rich phase. The works 
presented in literature are in general promising and report high e.e. or α values when 
compared to works involving other chiral selectors.  
Racemic ofloxacin was also enantioseparated with L-TA + HP-β-CD in a 
polymer+salt ABS with α = 1.32.[88] D,L-tryptophan was enantioseparated with β-CD 
in an ethanol+salt ABS with α = 1.38.[83] As presented in Table 2, the 
enantioselectivity of L-tryptophan with BSA using a polymer+polymer ABS is better, 
with an enantioselectivity of α = 3.1. Thus, proteins can be efficient chiral selectors in 
ABS.  
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Table 2 - Proteins as chiral selector in chiral ABS. 
Protein ABS Enantiomers Enantioselectivity Ref. 
Ovomucoid PEG+Dextran Carvedilol Not occurred [78] 
 PEG+Dextran DG-5128 Not occurred [78] 
BSA PEG+Na2HPO4 D,L-Kynurenine Not determined [80] 
 PEG+Dextran Ofloxacin e.e. = 62% [78] 
 PEG+Dextran L-tryptophan α = 3.1 [123] 
 In spite of the promising results achieved, few articles exists and the role of 
proteins as chiral selectors in ABS remains misunderstood. Moreover, having in mind 
the multiple proteins that are known up to date, the works reported in literature are 
limited, with BSA being the most studied. However, screening the proteins to find the 
ideal one to be used as chiral selector in ABS for a specific resolution application will 
be only done by performing multiple experiments, taking a long time and spending 
large amounts of reagents. In order to overcome these problems, there is an urgent 
demand to find computational tools able to predict protein-enantiomers interactions. 
 
1.2.2. Molecular docking - virtual screening of proteins as chiral selectors 
Molecular Docking (MD) is a virtual screening method that has been receiving a 
crescent attention mainly because it is believed that this method allows understanding 
the interactions between small chemical molecules and a protein at molecular level, in a 
fast, easy and highly accurate way (Figure 8).[125] MD algorithms provide quantitative 
predictions of docking binding energy, allowing predicting the most stable binding 
affinity between several molecules and proteins. MD is also applied to explain 
fundamental biochemical processes and their related experimental data, since it allows 
predicting how ligand-protein complexes occur.[126]  
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Figure 8- Scheme of the molecular docking method: ligand (green); receptor (grey); molecular 
interactions (yellow dashed line). 
 
MD has demonstrated to be a promising approach to identify protein 
enantioselectivity, by predicting enantiomer-protein (ligand- receptor) affinities, for 
example between acetochlor-interleukin 1,[127] diastereomeric heterodimers- 
acetylcholinesterase,[128] 4-phenyl-2-dimethylaminotetralin-G protein[129] and 
omeprazole-cytochrome P450.[130] In Table 3, several MD algorithms employed to 
explain protein enantiorecognition mechanisms are displayed. Each method applies 
different algorithms.[132–134] In some of these algorithms the ligand is incrementally 
designed, starting from docked ‘base fragment’, such as in DOCK[134] and 
FlexX.[135] However, using AutoDock[136] and Genetic Optimization for Ligand 
Docking (GOLD),[137] the interactions between the ligand and full receptor are taken 
into account. AutoDock works with the Lamarckian genetic algorithm (GA),[138] the 
SLIDE and Glide are supported by descriptor matching, FRED[139] (Algorithm that 
apply shape matching using gaussian functions) and Surflex Dock that is based on 
surface-based molecular similarity.[140] Besides ligand flexibility, receptor torsions are 
desirable in order to allow conformational changes that are required to bind the ligand 
with lower bind energy (induced fit phenomenon).[141] Due to the computational 
complexity, the receptor flexibility is unusual in most of the docking methods. 
FlexE[142] works using multiple receptor conformations, allowing any atoms torsion in 
a defined buffer region between the fixed and mobile regions. Another parameter is the 
software ability to support different number of atoms and rotatable bonds in the ligand 
structure. In summary, there are programs that maximize shape complementarity, often 
based on geometric criteria, and others incorporating an energy-driven or stochastic 
algorithm. Auto Dock presents a higher performance ability compared to other 
softwares, for example Glide,[131] that is limited at 200 atoms on ligand and the 
maximal number of rotatable bond of 35. In Auto Dock, the receptors are rigid 
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structures and the ligands are treated as flexible molecules with the number of active 
rotatable bonds ranging from 0 to 32. Moreover, there is no number of atoms limit, 
being this dictated by the receptor grid box.  
AutoDock Vina is a MD software, an update of AutoDock4, aiming to improve the 
binding mode accuracy.[143] AutoDock Vina predicts binding affinities between ligand 
and receptor, that can be used to predict where and which interactions occur at the level 
of receptor surface and which conformation could be the best fitting. Further speed-up 
is achieved from parallelism, by using multithreading on multicore machines. 
AutoDock Vina was already applied to select inhibitors with favorable interactions with 
2-Transenoylacyl carrier protein reductase in Mycobacterium tuberculosis.[144] The 
docking predicted structure ligand-receptor helped to identify a group of natural 
potential inhibitors which displayed high binding affinities for protein. Thus, these 
molecules could potentially inhibit the protein and be the basis to develop, for example, 
new anti-tuberculosis drugs. AutoDock Vina was more accurate and ten times faster 
compared to last version AutoDock4. [145] Based on this, AutoDock Vina displayed 
more advantages compared to traditional MD softwares, promoting accurate predictions 
with no cost of acquisition.  
Since this type of software can predict the affinities and interactions established 
between the enantiomers and proteins, it can be useful to predict the ability of a protein 
to act as chiral selector in ABS. 
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Table 3- Some examples of ligand-protein complexes prediction using Molecular Docking methods. 
Method Protein Enantiomers Application Ref. 
Molegro Virtual Docker Human serum paraoxonase 1 Sarin, soman and VX Biocatalysis [146] 
Maestro 
Potato epoxide hydrolase 
Benzyloxirane and 3-phenylpropane-1,2-
diol  
Biocatalysis [147] 
hCE2 and mfCES2v3 
O-n-valeryl propranolol, O-2-methyl-n-
butyryl propranolol and O-3-methyl-n-
butyryl propranolol 
Biocatalysis [148] 
Molecular Operating Environment 
Cereblon 
Thalidomide, lenalidomide, and 
pomalidomide 
Drug design [149] 
LdisPBP1 and LdisPBP2 
(7,8)-epoxy-2-methyloctadecane, Dis), 5-
oxadisparlure (5-oxaDis), 10-
oxadisparlure (10-oxaDis), 5-
thiadisparlure (5-thiaDis) and 10-
thiadisparlure(10-thiaDis) 
Binding assays [150] 
AutoDock 4.0 
Cucumber mosaic virus coat 
protein (CMV-CP) 
α-aminophosphonates Antiviral activity [151] 
AutoDock Vina Penicillin G acylase N-phenylacetyl amino acid Biocatalysis [152] 
Extra Precision (XP) Glide 4.5 
Cathepsin L –like cysteine 
proteases 
Thiocarbazate Binding assays [153] 
QUANTUM 3.3 
Leishmania donovani PTR1 
(LdPTR1) 
Monastrol Drug Design [154] 
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1.3. Carbohydrates as chiral selectors 
Another example of chiral selectors are carbohydrates. They present chirality being 
promising alternatives for chiral resolution applications. Cyclodextrins (CD) are the most 
common carbohydrates derivatives used as chiral selector in techniques such as capillary 
electrophoresis (CE) and counter current chromatography (CCC). Maruszak et al. [155] 
have incorporated β-CD in CE, showing that this was capable of discriminating different 
neurotransmissors as DOPA or phenylalanine. Polysaccharides and their derivates are 
extensively used as chromatographic chiral selectors in chiral stationary phases for the 
separation of enantiomers by HPLC. In the work of Matarasvihili et al. [156], the 
separation of 10 chiral arylpropionic acids derivates (AADs) using polysaccharide-based 
chiral HPLC columns was successfully achieved. Cellulose and amylose were studied, 
being the only difference in the linkage between the glucopyranose units (α in amylose and 
β in cellulose). This difference affected the chiral recognition, changing the retention time 
of the enantiomers being separated. In the work of Sun and Yuan [157], arabinose and 
ribose were integrated in different silica-based analytical columns. In the case of arabinose, 
benzoin enantiomers were resolved and in the ribose column there was a discrimination of 
trans-stilbene. This suggests that different carbohydrates can discriminate different 
compounds.  
These enantiomeric recognition mechanisms are utile for the development of 
successful enantioseparation techniques. Sucrose and cyclodextrins and their derivates are 
the most commonly used carbohydrates in enantioseparation processes. The most common 
technique with carbohydrates as chiral is CE, as shown in Table 4.   
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Table 4 - Some examples of carbohydrates as chiral selectors used in different enantioseparation methods. 
Type Carbohydrate Enantiomers 
Enantioseparation 
method 
Ref. 
Monosaccharide 
Glucose 
Binaphthyl enantiomers (BNA, BNP) CE [158] 
D-serine CE [159] 
Mannose Binaphthyl enantiomers (BNA,BNP) CE [158] 
Fructose D-serine CE [159] 
Galactose Binaphthyl enantiomers (BNA, BNP) CE [158] 
Ribose Trans-stilbene HPLC [157] 
Xylose Binaphthyl enantiomers (BNA, BNP) CE [158] 
Arabinose 
Binaphthyl enantiomers (BNA, BNP) CE [158] 
Benzoin HPLC [157] 
Disaccharide 
Sucrose 
Metalaxyl enantiomers UV-vis spectroscopy [160] 
Phenylalanine UV-vis spectroscopy [161] 
D-serine CE [159] 
Maltose Citalaprom (CIT) CE [162] 
Lactose D-serine CE [159] 
Polysaccharide 
Glycogen Basic drugs (CIT, NEF, CET), acid drugs (IBU) CE [163] 
Cellulose Naproxen, ibuprofen, fenoprofen, indoprofen HPLC [156] 
Amylose 
1,1'-binaphthyl-2,2'-diyl hydrogen phosphate (BDHP) CE [164] 
Naproxen, ibuprofen, fenoprofen, indoprofen HPLC [156] 
Derivate CD 
Serotonin, phenylalanine, dopamine, adrenaline, ephedrine, 
propranolol and DOPA 
CE [155] 
(R,S)-naproxen CCC [165] 
Mandelic acid derivates enantiomers HPLC [166] 
Phenylsuccinic acid CCC [167] 
22 
 
1.3.1. Aqueous biphasic systems with sugar as phase former and chiral selector 
Carbohydrates are compounds easily found in nature that present no charge, are 
biodegradability and lack toxicity, what makes their application in ABS an eco-friendly 
alternative to the use of the common high charge density salts. Carbohydrates have high 
affinity for water and salting-out aptitude, due to the several –OH groups with 
donor/acceptor character that they possess in their structures. Polymers [65] and ILs 
[69] are examples of phase formers with which carbohydrates can be combined to form 
ABS. Sadeghi et al. [65] screened several carbohydrates with PPGs and PEGs of 
multiple molecular weights to develop novel, more biocompatible ABS. Also, Taha et 
al. [168] applied polymer+sucrose-based ABS to extract BSA, with enhanced 
biocompatibilities achieved. To overcome the high viscosity of the polymer-rich phase, 
Zhang et al. [169] showed the possibility of creating 1-Butyl-3-methylimidazolium 
tetrafluoroborate ([C4mim][BF4])+fructose-based systems. Since [C4mim][BF4] is 
hydrolyzed in aqueous medium, Freire et al. [69] tested different carbohydrates paired 
with the water-stable 1-butyl-3-methylimidazolium trifluoromethanesulfonate 
([C4mim][CF3SO3]) to form ABS. From these works, and others where polar organic 
solvents were used [62,63], the possibility of pairing carbohydrates with multiple other 
phase forming agents creates the possibility to have a versatile separation platform.  
The works reported in literature for the application of sugar-based ABS in chiral 
resolution lay mainly on their use as chiral selectors added as an extra compound 
[81,87]. These are overviewed in Table 5. CD and their derivatives are the only used 
compounds, with promising results of enantioselectivity up to 68% of enantiomeric 
excess. Some works [76,83,84] report the use of newly synthesized CD derivatives 
simultaneously as phase formers and chiral selectors, however with lower 
enantioselectivities (up to 33% of enantiomeric excess). The main advantage of this 
second option, as already mentioned, is the simpler constitution of the ABS. However, 
the CD derivatives used so far involve complex synthetic routes [154,164,165] and the 
possibility of using less complex, naturally occurring carbohydrates as phase formers 
and chiral selectors for chiral resolution in ABS was never reported. 
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Table 5 - Carbohydrates as chiral selectors in chiral ABS. 
Carbohydrate ABS Enantiomers Enantioselectivity Ref. 
β-CD PEG2000+(NH4)2SO4 
Mandelic acid; 
Phenylalanine 
α=2.46; α=1.53 and 
e.e.= 12.8% 
[81], 
[170] 
 Ethanol+(NH4)2SO4 Tryptophan α=1.38 [83] 
Cu2-β-CD 
complex 
Triton X-114 Mandelic acid e.e.=68% [91] 
 
PEG 6000+ 
Na3C6H5O7 
α-
cyclohexylman
delic acid 
α=1.36 [79] 
Sulfonated-β-CD Ethanol+(NH4)2SO4 Mandelic acid α=1.69; e.e.=16.3% [93] 
hydroxypropyl-β-
CD 
[C4mim][BF4]+ 
(NH4)2SO4 
α-
cyclohexylman
delic acid 
α=1.59 [92] 
 PEG2000+(NH4)2SO4 
Phenylsuccinic 
acid; ofloxacin 
α=1.99 and 
e.e.=23.5%; α=1.32 
(with second chiral 
selector) 
[88], 
[171] 
 Ethanol+(NH4)2SO4 
Phenylsuccinic 
acid 
α=1.42; α=4.06 and 
e.e.=57.9% (with 
second chiral 
selector) 
[82], 
[90] 
Thermosensitive 
polymer 
Poly(MAH-β-
CD-co-NIPAAm) 
Poly(MAH-β-CD-co-
NIPAAm)+DexT40 
Mandelic acid α=1.27 [77] 
carboxymethyl-β-
CD 
1-propanol+ 
carboxymethyl-β-
cyclodextrin 
Zopiclone 
α=2.58 and 
e.e.=32.7% 
[84] 
Sulfobutyl ether-
β-CD 
Acetone+ Sulfobutyl 
ether-β-CD 
Phenylsuccinic 
acid 
α=2.1 and 
e.e.=31.7% 
[85] 
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1.4. Scopes and objectives 
Given the good ability of ABS to keep proteins structure and stability if well 
optimized,[56] the use of proteins in ABS for chiral resolution approaches can be seen 
as a promising alternative. Although some works have already reported this approach, 
the type of ABS tested is still limited if considering the structural diversity that they 
possess. Systems formed by polymer-polymer[56,172] and polymer-salt [173], 
polymer-IL [174] or even salt-IL [175] are some of the combinations already used to 
purify proteins. However, the range of proteins studied is limited (only BSA and 
ovomucoid are reported) as well as and the understanding on their mechanisms to act as 
chiral selectors within these systems.[77,79] Under this scenario, the main objective of 
this thesis is to enlarge the number and type of ABS and proteins that can be used for 
chiral resolution. In order to accomplish this objective, several tasks were developed 
according to Figure 9. 
First, ABS using proteins as chiral selectors will be focused. A bioinformatic tool 
will be used to predict the interactions between the MA enantiomers and different 
proteins, trying to find the ideal protein to enantioseparate MA. AutoDock Vina will be 
the autodocking tool used, since it is able to distinguish the interactions that occur 
between a certain protein and the two enantiomers of a certain compound in an accurate, 
quick and free way. Based on such predictions, two different proteins, one ideal, protein 
that display enantioselectivity, and other not ideal, will be chosen to screen different 
types of ABS (polymer-polymer, polymer-salt, IL-salt, IL-polymer, among others) for 
chiral resolution purposes. 
Owing to the several pairs of phase formers that can be used to form ABS, it is 
possible to identify a poor exploitation of these systems for enantioseparations. While 
the most conventional polymer-polymer and polymer-salt pairs are well-studied, others 
remain poorly studied. Also, some naturally occurring chiral compounds can be used to 
form ABS, where carbohydrates [69] and amino acids [71,174] are included. Moreover, 
the operational simplicity of the previous approach (where proteins are used as an extra 
chiral selector) can be improved. In this ambit, carbohydrates can be applied as natural 
phase formers and chiral selectors in ABS. Particularly, systems composed of sucrose 
and polymers or ILs will be exploited. 
In order to develop this enantioseparation platform, 2-hydroxy-2-phenylacetic acid, 
commonly known as mandelic acid (MA), was used as the model chiral compound. MA 
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is an aromatic compound with the molecular formula C8H8O3 (Figure 1), with the R and 
S enantiomers differing in the C2, with a rotation on this position. It was chosen as the 
model drug for this study, since it is widely used by several industries and their two 
enantiomers do not display the same activity what justifies the need for their separation. 
The enantiomer R is used in pharmaceutics as intermediate for the synthesis of 
antibiotics like penicillin[177] and in cosmetics for skin care products, to treat cases of 
photo-aging and acne due to its antibacterial action.[178] R-MA is also used as chiral 
resolving agent for the synthesis of anti-tumour agents.[179] 
 
Figure 9 - Summary of the tasks and objectives involved in the present thesis. 
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2. Experimental section 
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2.1. Chemicals and biomolecules 
The R and S enantiomers of MA (purity = 99 wt%) were both acquired from Acros 
Organics. The Cyt C from equine heart (purity > 95 wt%) was obtained from Sigma-
Aldrich. The BSA (fatty acid free) was purchased from Fisher Scientific. A phosphate 
buffer saline (PBS) solution was prepared at pH 7.4, using PBS tablet from Sigma-
Aldrich. 
The polymers used in ABS preparation were polyethylene glycol Mn 400 and 3350, 
PEG 400 and PEG 3350, polypropylene glycol Mn 400, PPG 400, and dextran from 
Leuconostoc spp. Mn 450 000-650 000, Dex 500. All of them were acquired from 
Sigma- Aldrich. The salts used were sodium sulphate, Na2SO4 (purity = 99 wt%), from 
Sigma-Aldrich and tri-potassium citrate monohydrate, K3C6H5O7, from Prolabo. Citric 
acid, C6H807 (purity = 100 wt%) was purchased at Fisher Scientific. The two latter 
compounds were used together to prepare citrate buffer at pH 7. The imidazolium-based 
ILs employed were acquired at IoLiTec and were 1-butyl-3-methylimidazolium 
chloride, [C4mim]Cl (purity = 99 wt%) and 1-butyl-3-methylimidazolium 
trifluoromethanesulfonate, [C4mim][CF3SO3] (purity = 99 wt%). The cholinium-based 
compounds, cholinium dihydrogen citrate, [Ch][DHCit] (purity 99 wt%)and cholinium 
acetate, [Ch][Ac] (purity > 99 wt%) were from Sigma-Aldrich, Acros Organics and 
IoLiTec, respectively. The remaining ILs used belong to the phosphonium and 
quaternary ammonium families, namely triisobutyl(methyl)phosphonium tosylate, 
[Pi(444)l][Tos] (purity > 95 wt%), tetrabutylphosphonium chloride, [P4444]Cl (purity > 95 
wt%), both from Cytec and tetrabutylammonium chloride, [N4444]Cl (purity ≥ 97 wt%) 
from Sigma-Aldrich. All the chemical structures of polymers, ILs and (D)-sucrose are 
presented in Figure 10. 
The mobile phase used in HPLC analysis was composed of L-phenylalanine, L-Phe 
(purity = 99 wt%) acquired from Alfa Aesar, copper sulfate pentahydrate, CuSO4.5H2O 
(purity = 99.5wt%) purchased from BDH chemicals, methanol (HPLC grade) was from 
CHEM-LAB and ultra-pure water, which was double distilled, passed by a reverse 
osmosis system and further treated with a Milli-Q plus 185 water purification apparatus. 
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Figure 10 - Chemical structures of the compounds used in the ABS preparation. 
 
2.2. Experimental 
2.2.1. Partition studies of mandelic acid enantiomers in different chiral ABS 
Different two-phase mixture compositions were used in the preparation of ABS, 
according to the position of the binodal curves reported in literature (Table 6 to 8). Due 
to the distinct aptitude of different systems to form two phases, distinct mixture points 
were selected to perform this initial screening. The total mass of each system was 3 
grams and the correct amount of each phase former was added within an uncertainty of 
10-4 g, according to Table 6 and 7. Two studies were done, one where the partition of 
the protein and the enantiomers was performed separately and another where the protein 
and the enantiomers coexisted inside the same ABS. The solution containing the protein 
and/or the enantiomers was prepared at a concentration of 1 g.L -1 of protein (Cyt C or 
BSA) and/or 10.4 g.L-1 of each mandelic acid enantiomer. At the end, R-MA and S-MA 
are present at a concentration of 4.2 mg per g of ABS. These components were prepared 
in PBS. The solution composed by enantiomers and protein was left overnight, to 
promote interactions between them and the thermodynamic equilibrium for the 
complete migration of each enantiomer for each phase. The two phases (top and bottom) 
were separated and weighed for posterior quantification of enantiomers in HPLC. In 
Tables 6 to 8 are represented the different ABS with the composition and phases 
identification. 
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The parameters calculated to evaluate the ability of the different proteins to separate 
the two enantiomers of MA are indicated in Equations 1-3 as follows. 
   (1) 
  (2) 
 (3) 
 
In these equations, mR-MA CS rich-phase and mS-MA CS rich-phase are, respectively the mass 
of the R and S enantiomers in the chiral selector rich-phase. The m0R-MA and m0S-MA 
corresponds to the initial mass of R and S enantiomers present in the ABS. mR-MA CS-rich -
phase, and mS-MA CSrich-phase are, respectively, the mass of S and R enantiomers in chiral 
selector rich-phases. The chiral selector rich-phase corresponds to the phase of the ABS 
wherein the protein/(D)-sucrose tend to be more present, in other words, the most 
appropriate “phase” to attest the enantioselective patterns. 
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Table 6 - Mixture points composition used in the partition studies of MA enantiomers using ABS containing cytochrome C as the chiral selector. 
ABS Phase formers Mixture point composition Phases identification  
Type 1 2 
1 / 
(wt%) 
2 / 
(wt%) 
R/S-MA+Cyt C 
aqueous solution / 
(wt%) 
PBS / 
(wt%) 
Top phase Bottom phase Ref. 
Polymer-salt PEG400 Na2SO4 22 12 40 26 PEG Salt [180] 
Polymer-IL 
PPG400 
[Ch][DHP] 30 30 40 - PPG IL [181] 
Polymer-polymer 
PEG400 25 35 40 - PPG PEG [56] 
PEG3350 Dex500 5 15 40 40 PEG Dex [172] 
IL-salt [C4mim]Cl C6H5K3O7 22 33 40 5 IL Salt [182] 
 
Table 7 - Mixture points composition used in the partitioning studies of mandelic acid enantiomers using ABS containing BSA as the chiral selector. 
ABS Phase formers Mixture point composition Phases identification  
Type 1 2 
1 / 
(wt%) 
2 / 
(wt%) 
R/S-MA+BSA 
aqueous solution / 
(wt%) 
PBS / 
(wt%) 
Top phase Bottom phase Ref. 
Polymer-IL 
PPG400 
[Ch][Ac] 30 30 40 - PPG IL 
[181] 
[Ch][DHCit] 30 30 40 - PPG IL 
Polymer-salt Na2SO4 32 12 40 16 PPG Salt [183] 
Polymer-sugar (D)-Sucrose 30 30 40 - PPG (D)-Sucrose [168] 
Polymer-polymer 
PEG400 35 25 40 - PPG PEG [56] 
PEG3350 Dex500 5 15 40 40 PEG Dex [172] 
Salt-IL 
K3C6H5O7/
C6H5O7  
at pH 6 
[Pi(444)l][Tos] 15 30 40 15 IL Salt 
[175] [P4444]Cl 15 30 40 15 IL Salt 
[N4444]Cl 15 30 40 15 IL Salt 
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Table 8- Mixture points composition used in the partition studies of MA enantiomers using ABS composed of sucrose. 
 Phase formers Mixture point composition Phases identification  
Type 1 2 
1 / 
(wt%) 
2 / 
(wt%) 
R/S-MA aqueous 
solution / (wt%) 
PBS / 
(wt%) 
Top 
phase 
Bottom 
phase 
Ref. 
Polymer-sugar PPG400 
(D-)Sucrose 
20 40 40 - 
PPG 
(D)-Sucrose 
[168] 30 30 40 - 
26 26 40 8 
IL-sugar [C4mim][CF3SO3] 20 40 40 - IL [69] 
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2.2.2. Mandelic acid enantiomers quantification 
The quantification of the two enantiomers of MA was done by HPLC-DAD by a 
method developed and validated in our research group, based on a protocol previously 
reported in literature.[184] The liquid chromatograph was a HPLC Elite LaChrom 
(VWR Hitachi) possessing a diode array detector (DAD) l-2455, column oven l-2300, 
auto-sampler l-2200 and pump l-2130. The analytical column was constituted by a 
sorbent LiChrospher 100 RP-18 (5μm) and cartridge LiChroCART 250-4 HPLC-
Cartridge, linked to a 5 μm, 4 mm × 4 mm guard column with the same stationary 
phase. The analytical column was from Merck. The mobile phase was chiral and it was 
prepared by mixing 15 wt% of methanol and 85 wt% of ultrapure water, containing 2 
mM of L-phenylalanine and 1 mM of CuSO4. Whenever necessary, the pH of the 
mobile phase was corrected to 4.00 by adding an aqueous solution of ammonia (5 wt%). 
The mobile phase was then filtered under vacuum using regenerated cellulose 
membrane filters (0.45 μm) and degassed in an ultrasound bath. The chromatographic 
separation was done under isocratic mode, at a flow-rate of 0.8 mL.min-1 for 20 
minutes. The injection volume was 20 μL, the DAD detector measured at 270 nm, the 
column oven temperature was 22 ºC and the autosampler temperature was 25 °C. The 
quantification was based on a calibration curve previously determined (Appendix A), 
based on 8 standard solutions of known concentrations of each enantiomer (10 – 1000 
mg.L-1) in water:methanol (85 wt%:15 wt%) against the corresponding peak areas. Each 
system was done in quadriplicate and at least two injections per sample were done. 
All ABS phases were filtrated and diluted 100 times in a solution of water (85 
wt%) and methanol (15 wt%). By integrating the peaks, it was possible to quantify each 
enantiomer, once they possess different retention times. R-MA elutes first at 11 min 
followed by S-MA which elutes at 13 min. 
 
2.2.3. Proteins’ quantification 
For proteins’ quantification, the same mixtures points were prepared as those 
indicated in Tables 6 and 7 with the presence of the protein solution (1 g.L-1) in PBS 
only. The phases were separated and weighed. Cyt C and BSA were quantified at 410 
nm and 280 nm, respectively, using a UV-Vis microplate reader (Synergy HT micro-
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plate reader - BioTek). The extraction efficiency of the proteins was calculated through 
Equation 4. Each sample was analysed at least three times. 
 
  (4) 
 
Absprot-rich and Absother are the values of absorbance in the protein rich phase and the 
other phase, top or bottom, depending on the protein migration. Blank controls (ABS 
where no protein was added) were applied to discount any interference coming from the 
phase constituents. wprot-rich and wother is the weight of the protein rich-phase and the 
other phase, respectively. the extraction efficiency of the Cyt C was evaluated for five 
systems: PEG400+Na2SO4, PPG400+[Ch][DHP], PEG400+PPG400, 
PEG3350+Dex500 and [C4mim]Cl+C6H5K3O7. For BSA, it was only calculated E.E.prot 
for PEG3350+Dex500, PEG400+PPG400 and PPG400+Na2SO4. 
 
2.2.4. Molecular docking 
The interaction sites of proteins with the MA enantiomers were identified using the 
Auto-dock vina 1.1.2 program.[143] The crystal structures of BSA (4F5S), CytC 
(1HRC), Human serum albumin (HSA) (1E7I), Bromelain (1W0Q), Hexokinase II 
(1IG8), Amylase (1UA7), Green fluorescent protein (GFP) (4KW4), Laccase (1KYA), 
Lysozyme (4YM8), Ovalbumin (1OVA) and Phycoerythrin (1EYX) were used in the 
molecular docking, where the Auto DockTools (ADT)[138]  was used to prepare the 
proteins input files by merging non-polar hydrogen atoms, adding partial charges and 
atom types. Ligand (S- and R- mandelic acid) 3D atomic coordinates were computed by 
Gaussian 03w and ligand rigid root was generated using ADT, setting all possible 
rotatable bonds defined as active by torsions. The grid center at the center of mass (x-, 
y-, and z-axes, respectively) to cover the whole interaction surface of: BSA (126 Å × 68 
Å × 96 Å), CytC (40 Å × 40 Å × 40 Å), HSA (92 Å × 52 Å × 92 Å), Bromelain (58 Å × 
46 Å × 48 Å), Hexokinase II (62 Å × 80 Å × 56 Å), Amylase (52 Å × 54 Å × 76 Å), 
GFP (48 Å × 60 Å × 44 Å), Laccase (54 Å × 64 Å × 72 Å), Lysozyme (40 Å × 46 Å × 
46 Å), Ovalbumin (74 Å × 46 Å × 60 Å) and Phycoerythrin (50 Å × 64 Å × 40 Å). The 
binding model that has the lowest binding free energy was searched out from 9 different 
conformers for each ligand (MA enantiomers). 
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discussion 
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3.1. Protein as chiral selectors in ABS for MA enantioseparation 
 
The molecular docking was already used in other works to predict interactions and 
affinities between proteins and chiral ligands, as overviewed in Table 3. A screening of 
several proteins using molecular docking was done to predict the interactions with MA 
enantiomers. The proteins incorporated as chiral selectors in the ABS were chosen 
according to the results obtained by molecular docking, namely BSA and Cyt C. 
The ability of ABS for the extraction and purification of BSA and Cyt C was 
already shown[68] by using polymer-salt,[185], IL-salt,[186,174], polymer-
polymer[187][54] and polymer-IL[168] systems. In this context, and considering the 
stability of the proteins in these systems, a screening of several types of ABS composed 
of polymer-polymer, polymer-IL, salt-IL, polymer-sugar and containing Cyt C or BSA 
as chiral selectors was performed. This allowed evaluating the ABS chiral resolution 
ability for racemic MA regarding two main aspects: (i) the interactions occurring 
between the MA enantiomers and the protein and (ii) the type of phase formers yielding 
the adequate interactions (electrostatic, hydrophobic, hydrogen bonding) for chiral 
resolution to take place. At the end, it was also possible to conclude on the molecular 
docking ability to be used as a predicting tool to design chiral resolution approaches 
based on ABS containing proteins as the chiral selectors. 
 
3.1.1. Molecular docking 
In order to evaluate the enantiomers interactions with proteins, molecular docking 
using Autodock Vina was applied. The 3D structures were prepared using Discovery 
Studios 2016. Several proteins were tested, namely Cyt C, BSA, HSA, Bromelain, 
Hexokinase II, Amylase, Green Fluorescent Protein (GFP), Laccase, Lysozyme, 
Ovalbumin and Phycoerythrin. All proteins’ 3D structure was obtained from RSCB 
Protein Data Bank (PDB). The objective was to identify the protein capable to establish 
a selective interaction with one of the MA enantiomers. Therefore, different parameters 
were observed to select the ideal protein to enantioseparate MA such as, the interaction 
of amino acids residues, docking affinity (kcal.mol-1), type of interactions and geometry 
distance (Å) of each MA enantiomers. The results are presented in Tables B.1-B.9 and 
Figures B.1-B.9 in Appendix B. Since the lowest absolute value of affinity bind pose 
(kcal.mol-1) for MA enantiomers was similar for both structures (R- and S- MA), the 
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specific interactions and interacting amino acids residues provide more details about the 
docking affinity on protein structure. Based on this, the proteins were classified into two 
categories: competitive and non-competitive (similar and non-similar amino acid 
residues interaction, respectively). The proteins showing MA-enantiomers competitive 
behaviour were the bromelain, BSA, laccase, lysozyme and ovalbumin. Meanwhile, the 
proteins with non-competitive behaviour for MA-enantiomers were the Cyt C, HSA, 
Hexokinase II, Amylase, GFP, Ovalbumin and Phycoerythrin. Table 9 depictes the 
complete list of proteins studied. The ideal protein should present a competitive 
behaviour (similar bidding site for both MA enantiomers in protein structure), where 
only one of the MA enantiomers will present more affinity and strong interactions with 
the amino acids residues from the protein, allowing an efficient enantioseparation. 
According to computational screening performed, it was decided to analyse in more 
detail two proteins: BSA (competitive behaviour) and Cyt C (non-competitive). Both 
proteins were already extracted using ABS[78], [80], [123], those being thus the most 
appropriate to prove the ability of the selected proteins using molecular docking as 
chiral selectors for MA enantiomers. All data are discriminated in Appendix B. 
 
Table 9 - Enantioselectivity of proteins analysed with AutoDock Vina. 
Protein (PDB file) Enantioselective behaviour 
Cyt C (1HRC) Non-competitive 
BSA (4F5S) Competitive 
HSA (1E71) Non-competitive 
Bromelain (1W0Q) Competitive 
Hexokinase II (1IG8) Non-competitive 
Amylase (1UA7) Non-competitive 
GFP (4KW4) Non-competitive 
Laccase (1KYA) Competitive 
Lysozyme (4YM8) Competitive 
Ovalbumin (1OVA) Competitive 
Phycoerythrin (1EYX) Non-competitive 
 
Table 10 shows the results for the best binding pose Cyt C docking with the lowest 
absolute value of affinity (kcal.mol-1) for Cyt C with MA-enantiomers (docking 
affinities, interacting amino acids residues, type of interaction and geometry distance 
(Å) of MA-enantiomer individually). The best binding pose and type of interaction of 
Cyt C with MA-enantiomers are displayed in Figure 11.  
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Table 10 – Docking affinity energy and interacting amino acids predicted by AutoDock Vina for Cyt C- MA enantiomers. 
Cytochrome C 
(PDB:1HRC) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of interaction From To 
Distance  
(Å) 
R-MA -5.0 
Tyrosine67 
Hydrogen bond Tyr67 R-MA 3.88 
Hydrophobic 
Tyr67 R-MA 5.23 
Leucine32 R-MA Leu32 5.19 
Leucine35 R-MA Leu35 5.18 
S-MA -4.8 
Threonine19 
Hydrogen bond 
S-MA Thr19 2.61 
Alanine15 S-MA Ala15 2.86 
Phenilalanine10 
Hydrophobic 
Phe10 S-MA 4.82 
Alanine15 S-MA Ala15 4.75 
Valine20 S-MA Val20 5.30 
 
 
Figure 11 - The Cyt C docking pose with the lowest absolute value of affinity (kcal.mol-1) for Cyt C with (a) R-MA and (b) S-MA (----) hydrogen bond, (----) π-σ bond, (-
---) π-alkyl bond and (----) π – donor hydrogen bond).
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The results revealed that MA-enantiomers present different binding sites at Cyt C 
surface. The docking affinity for R-MA (-5.0 kcal.mol-1) is higher compared to S-MA (-
4.8 kcal.mol-1). The R-MA interact with three amino acids, namely Leu32, Leu35 and 
Tyr67 (by hydrogen bond and hydrophobic interactions). However, S-MA shown ability 
to bind to 4 amino acids (Phe10, Ala15, Thr19 and Val20) also by hydrogen bond and 
hydrophobic interactions. Analysing individually the interactions, S-MA establish more 
favourable interactions than R-MA. The interaction distance must be below 5Å to be 
considered a viable interaction. Thus, in presence of S-MA, the protein-enantiomer 
complex is more probable. The interaction of S-MA suggests that this enantiomer would 
be more capable of forming a protein-enantiomer complex, since it has four chemical 
bonds bellow 5 Å and the R-MA only one. The type of interaction that could be 
promoted by MA-enantiomers is also important to highlight. According to the 
interaction distance, the rank of possible interactions follows the order: hydrogen bond 
> ionic interaction > hydrophobic interaction > van der Waals interactions. In Cyt C-S-
MA complex, three hydrophobic interactions and two hydrogen bond interactions were 
predicted by molecular docking. On the other hand, Cyt C-R-MA complex is based in 
one hydrogen bond in Tyr67 residues. 
Since both MA-enantiomers present different binding sites on Cyt C surface, the protein 
studied seems to be inefficient for enantioselective separations of MA-enantiomers. On 
the other hand, BSA displays an opposite behaviour. The docking pose of BSA-MA 
enantiomers with the lowest absolute value of affinity (kcal.mol-1) are displayed in 
Figure 12. Docking affinities, interacting amino acids residues, type of interaction and 
geometry distance (Å) of MA-enantiomer individually and BSA are also shown in 
Table 11. 
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Table 11- Docking affinity energy and interacting amino acids predicted by AutoDock Vina for BSA-MA enantiomers. 
BSA 
(PDB:4F5S) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of interaction From To 
Distance 
(Å) 
R-MA -5.0 
Arginine208 
Hydrogen bond 
Arg208 R-MA 3.16 
Leucine346 
R-MA Leu346 2.07 
Hydrophobic 
R-MA Leu346 4.86 
Lysine350 R-MA Lys350 5.47 
Valine481 R-MA Val481 4.10 
S-MA -4.8 
Arginine208 
Hydrogen bond 
Arg208 S-MA 3.19 
Leucine346 S-MA Leu346 2.14 
Alanine209 
Hydrophobic 
S-MA Ala209 4.69 
Alanine212 S-MA Ala212 5.03 
Leucine346 S-MA Leu346 4.51 
Valine481 S-MA Val481 4.46 
 
Figure 12 - The BSA docking pose with the lowest absolute value of affinity (kcal.mol-1) for BSA with (a) R-MA and (b) S-MA (----) hydrogen bond and (----) π-alkyl 
bond.
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The results of BSA-MA enantiomers depicted in Figure 12 show that both MA-
enantiomers present similar binding sites to the BSA-surface. MA-enantiomers interact 
with Arg208, Leu346 and Val481. In fact, BSA was already applied as chiral selector in 
chromatography separation processes [107], [110], [112]. The complex formed between 
BSA-MA enantiomers presents the same trend on binding affinity complexes formed of 
Cyt C-MA enantiomers: -5.0 kcal.mol-1 for R-MA and -4.8 kcal.mol-1 for S-MA. 
However, BSA-MA enantiomers exhibit the enantioselective behaviour. 
In presence of both MA-enantiomers it was observed four common interactions with 
amino acids residues: two hydrogen bonds with Arg208 and Leu346 and two 
hydrophobic interactions with Leu346 and Val481. Besides the similar interactions, 
individually S-MA enantiomer present two hydrophobic interactions with Ala209 and 
Ala212 and R-MA enantiomer display one hydrophobic interaction (Lys350). 
Therefore, these results suggest that the R-MA enantiomers are more able to establish 
enantioselective interactions with BSA surface. Even, the interactions distances are 
lower in R-MA than S-MA, which seems to support that the BSA-R-MA complex will 
occur more easily than the BSA-S-MA complex. 
In summary, the results obtained indicate that in presence of BSA, MA-enantiomers 
will present similar binding sites on the protein surface showing the ability of BSA to 
promote an enantioseparation process. In order to validate the computational screening 
using AutoDock Vina, in next section the use of Cyt C and BSA as chiral selectors was 
tested regarding the use of several ABS composed of different phase-forming agents.  
 
3.1.2. Cyt C as chiral selector in ABS 
Cyt C is a hemeprotein associated with the inner membrane of the mitochondrion, 
being an essential component of the electron transport chain.[188] Cyt C is commonly 
obtained from equine heart and it is composed of 104 amino acids with ~12 kDa. This 
protein is normally used as a model protein for molecular evolution.[189] It was already 
used as a chiral selector in CEC by being incorporated in a stationary phase to separate 
an enantiomeric mixture of racemic amino acids. [190] 
The mixture points used in ABS preparation are described in Table 6 (Chapter 2, 
section 2.2.1). Firstly, the partition behaviour of Cyt C and each one of the mandelic 
acid enantiomers was performed separately. The results obtained for the partition of Cyt 
C in different ABS, namely polymer-polymer, polymer-salt and salt-IL, are reported in 
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Figure 11a. The E.E.Cyt C, E.E.R/S-MA and e.e. values were calculated to the phase where 
Cyt C was more concentrated and all detailed data is presented in Appendix C. 
 
Figure 13 - Extraction efficiencies of Cyt C (E.E.CytC, ), R-MA (E.E.R-MA ) and S-MA (E.E.S-MA,) 
along with the enantiomeric excess (e.e., ●) obtained for the ABS studied. (a) partition studies in ABS 
with MA racemate and Cyt C performed separately. (b) enantioseparation studies in ABS with MA 
racemate and Cyt C performed together. 
 
The protein’s partition is a complex process that depends on the interactions 
between the protein and the phase formers of the system. Many are the factors that 
affect the protein partition in any ABS, namely polymer’s molecular mass, size and 
concentration, salt’s ionic strength and medium pH. [54] The systems tested perform 
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according to the following decreasing order in what regards the concentration of Cyt C 
in a single phase (according to the E.E.Cyt C):  
PEG400+PPG400 (E.E.Cyt C = 93.99 ± 0.5%) > PEG400+Na2SO4 (E.E.Cyt C = 91.66 ± 
0.22%) > [C4mim]Cl+C6H5K3O7 (E.E.Cyt C = 89.44 ± 0.75%)  > PPG400+[Ch][DHP] 
(E.E.Cyt C = 86.13 ± 2.01%) > PEG3350+Dex500 (E.E.Cyt C = 70.74 ± 1.24%) 
In the systems composed of polymer+salt/IL, the protein partitions preferentially 
for the most hydrophilic Na2SO4/[Ch][DHP]-rich phase, with a E.E.Cyt C of 91.66 ± 
0.22% and 86.13 ± 2.01%, respectively. Moreover, and since PBS is used to keep the 
pH of the systems at pH 7.4, positively charged Cyt C is present (p.I. = 10-10.5).[191] 
This could explain the partition of the protein to the Na2SO4/[Ch][DHP]-rich phase 
since the amino acids on Cyt C’s surface will establish electrostatic interactions with the 
SO4
2-/[DHP]- anions. 
For the systems composed of two polymers, Cyt C is mainly present in the most 
hydrophilic (PEG400-rich or Dex500)-rich phase. When comparing the chemical 
structure of PPG400 and PEG400, PPG is more hydrophobic, since it is composed of an 
extra methyl group. Dextran, being a glucan, is more hydrophilic than PEG. Thereby, 
the protein partition seems to be driven by the polarity of the phases in 
polymer+polymer-based ABS.  
In the case of [C4mim]Cl+C6H5K3O7 system, the IL-rich phase is the phase 
enriched in Cyt C (E.E.Cyt C of 89.44 ± 0.75%), in spite of being the most hydrophobic 
phase. In this case, the Cyt C partition is driven by specific interactions with the IL. The 
protein is positively charged and will establish electrostatic interactions with the Cl- 
anion. Moreover, π-π interactions between the aromatic ring of the [C4mim]+ cation and 
the aromatic amino acid residues of the protein may also occur. 
In the same ways to the partition behaviour of the protein, the partition of MA 
enantiomers may also be influenced by several interactions occurring between the MA 
and the ABS phase formers. For the extraction of the enantiomers, the best order to 
extract the mandelic acid to one phase is (according to the E.E.R-MA/S-MA values):  
PEG400+PPG400 > [C4mim]Cl+C6H5K3O7  > PPG400+[Ch][DHP] > 
PEG3350+Dex500 > PEG400+Na2SO4  
For the systems composed of polymer+salt/IL, the PEG400+Na2SO4 ABS performs 
better at extracting both enantiomers to the PEG-rich phase, with a very low amount of 
MA migrating to the salt-rich phase, as represented in Figure 13a. This is a consequence 
of the higher hydrophobicity of MA, as indicated by the logarithmic function of its 
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octanol-water partition coefficient (log Kow) of 0.90.[192] However, in both IL-based 
ABS, a similar partition between the two phases is observed and a relationship between 
the polarity of the phases and the extraction efficiency of MA is not observed. This 
indicates that ILs are able to interact specifically with MA enantiomers. 
In the case of polymer-polymer systems, the PEG3350+Dex500 system induces an 
almost equivalent partition of the enantiomers to both phases (E.E.R-MA = 40.69 ± 2.02% 
and E.E.S-MA = 46.40 ± 1.56%), while PEG400+PPG400-based ABS yields a more 
significant partition to the more hydrophilic PEG-rich phase (E.E.R-MA = 59.44 ± 1.62% 
and E.E.S-MA = 73.82 ± 1.68%). The difference in the hydrophobicity/hydrophilicity of 
the phases is more important for PEG400+PPG400 than for PEG3350+Dex500, what 
induces a more significant partition of the enantiomers to one phase. 
It should be noted that, since no chiral selector was added to these systems (with the 
exception for the Dex500-based ABS), no significant enantiomeric separation was 
expected as shown by the low e.e. values obtained (-9.8 ± 0.5% < e.e. < 1.2 ± 0.4%). To 
develop a system for chiral resolution, a system where the protein and the enantiomers 
partition to distinct phases may be the best option. The introduction of Cyt C may 
favour chiral interactions with only one enantiomer manipulating its partition to the 
other phase. In this context, the system composed of PEG400 and Na2SO4 seems to be 
the best option because Cyt C partitions to the salt-rich phase and the enantiomers to the 
polymer-rich layer. In this sense, and having studied the partition of the protein and 
both enantiomers separately, it was then proceed the test using the protein and the 
enantiomers simultaneously in the same systems to validate their real chiral resolution. 
The results obtained for the E.E. and e.e. are shown in Figure 13b and all data are 
discriminated in Appendix C. 
The introduction of Cyt C in the systems here studied was shown to influence the 
partition of the enantiomers. The enantioseparation aptitude of the Cyt C containing 
ABS follows the decreasing order (based on the e.e. values): 
PPG400+[Ch][DHP] (e.e. = -9.0 ± 1.2%) > PEG3350+Dex500 (e.e. = 6.3 ± 1.6%) > 
[C4mim]Cl+C6H5K3O7 (e.e. = 5.0 ± 2.0%) > PEG400+PPG400 (e.e. = 1.9 ± 0.9%) 
>PEG400+Na2SO4 (e.e. = 1.2 ± 0.4%) 
In general, and as corroborated by the molecular docking results, no significant 
improvements were caused by the presence of Cyt C in the ABS screened. 
PPG400+[Ch][DHP]+Cyt C-based ABS yielded an e.e. = -9.0 ± 1.2% – the best result 
achieved – whereas, PEG400+Na2SO4+Cyt C failed in the separation of the enantiomers 
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(e.e. = 1.2 ± 0.4%). Not only the inability of the protein to act as chiral selector, but also 
the salting-out power of Na2SO4 may contribute for this result. The introduction of Cyt 
C in the [C4mim]Cl+C6H5K3O7 system increased the presence of R-MA in the IL rich-
phase up to e.e. = 5.0 ± 1.0%. By now, the choice of strong salting-out agents, as 
Na2SO4 or C6H5K3O7, seems to negatively affect the enantioseparation. 
Polymer+polymer systems dismiss the use of salting out agents as they are formed 
by the incompatibility of the polymers in aqueous solution. In the PEG400+PPG400 
system, no significant enantioselectivity was observed (e.e. = 1.2 ± 0.9%), opposing to 
the other polymer-polymer system (PEG3350+Dex500) where the e.e. varied from -4.8 
± 0.9% (for S-MA) to 6.3 ± 1.6% (for R-MA). Dextran, being a glucan, may display 
some chirality and thus, induce some enantioseparation without the presence of Cyt C. 
The presence of Cyt C, by its side, plays a certain role in this specific ABS as it 
intensifies the presence of R-MA opposing to S-MA. Furthermore, PEG3350+Dex500 
has a more tenuous difference between the phases’ polarities allowing a better 
enantioseparation than the PEG400+PPG400 ABS. 
These results indicate the importance of choosing the adequate phase formers and 
tuning their properties, namely salting-out of the salt and hydrophilic/hydrophobic 
differences of the phases, to achieve better enantioseparations. 
 
3.1.3. BSA as chiral selector in ABS 
BSA is a bovine serum albumin responsible by the blood transport in the species 
Bos taurus. It is constituted by 583 amino acids and the molecular weight is 66.5 kDa. 
Beyond the BSA low cost, which is a useful feature for the economic viability of the 
chiral ABS development, its ability to act as chiral selector was already shown (Chapter 
1.2, Tables 1 and 2). Techniques such as chromatography [102,109], membrane-based 
separations[104,112] and ABS [78] are some examples.  
Some ABS reported in literature show the outstanding ability to completely extract 
BSA into a single phase.[173,179] In this context, in this section, the types of ABS 
tested were chosen based on the extraction results reported in literature: for the IL/salt 
and IL+polymer systems studied, the E.E.BSA results used were those reported by 
Pereira et al.[175] and Quental et al.[181]; and for the polymer+ (D)-sucrose, the results 
of BSA extraction were used from the results already reported by Taha et al. [168]. In 
order to enlarge the systems screened, the E.E.BSA for the ABS composed of 
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PPG400+Na2SO4, PPG400+PEG400 and PEG3350+Dex500 were determined in the 
present work to allow further enantioseparation studies. All detailed data is present in 
Appendix C. 
The following combinations were used: PPG400+[Ch][Ac][181], 
PPG400+[Ch][DHCit][181], PPG400+Na2SO4[183], PPG400+(D)-Sucrose[168], 
PPG400+PEG400[56], PEG3350+Dex500[172], [Pi(444)l][Tos]+Citrate buffer at pH 
6[175], [P4444]Cl+ K3C6H5O7/C6H5O7, at pH 6[175] and [N4444]Cl+ K3C6H5O7/C6H5O7 
at pH 6[175]. The ability of systems to concentrate BSA into a single phase is ranked as 
follows: 
[N4444]Cl+K3C6H5O7/C6H5O7 (E.E.BSA = 100%) = [P4444]Cl+K3C6H5O7/C6H5O7  
(E.E.BSA = 100%) = [Pi(444)l][Tos]+K3C6H5O7/C6H5O7 (E.E.BSA = 100%) = 
PPG400+[Ch][Ac] (E.E.BSA = 100%) = PPG400+[Ch][DHCit] (E.E.BSA = 100%) = 
PPG400+Sucrose (E.E.BSA = 100%) > PEG3350+Dex500 (E.E.BSA = 89.43 ± 1.24%) 
~ PEG400+PPG400 (E.E.BSA = 90.36 ± 0.5%) >> PPG400+Na2SO4 (E.E.BSA = 55.00 
± 2.55%) 
Considering the pI of BSA (4.8)[193] and  the pH medium used in the systems 
(PBS at pH = 7.4), the protein is negatively charged and electrostatic interactions 
between cations of IL and the amino acids on the BSA surface will be established. For 
the IL+salt ABS, BSA is completely extracted to the IL-rich phase. This behaviour was 
explained by Pereira et al.[175] by “a combined effect of favourable dispersive 
interactions, salting-out effect exerted by the citrate-based salt, and electrostatic 
interactions between the positively charged IL cations and the negatively charged amino 
acid residues at the surface of the protein”. For the PPG400+[Ch]-based ILs ABS, BSA 
migrates to the [Ch]-rich phase as a consequence of “a delicate balance among 
hydrogen bonding and dispersive interactions occurring between the protein and the IL 
ions”, as proposed by Quental et al.[181] The same phenomenon was verified for the 
partition of Cyt C in the same type of systems. Moreover, in the PPG+Na2SO4 system, 
the BSA has almost an equal partition to both phases. From the overall results for these 
three types of systems (IL+salt, IL+polymer and polymer+salt), it seems that ILs are 
able to establish specific interactions with the protein if well-designed, allowing to 
achieve single-step complete extractions.  
In both polymer+polymer systems, BSA partitions preferentially to the more 
hydrophilic phases, Dex500 rich- and PEG500-rich phases. Similarly, in PPG400+(D)-
sucrose, a complete partition of BSA to the most hydrophilic sugar-rich phase is 
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observed. This scenario indicates that BSA partition is dominated by the 
hydrophilicity/hydrophobicity of the phases in polymer+polymer and polymer+sugar 
systems, as also observed when Cyt C was used. 
For the extraction of the enantiomers, the order to extract MA enantiomers to one 
phase is the following (according to the E.E.R-MA/S-MA values):  
[N4444]Cl+K3C6H5O7/C6H5O7 > PPG400+[Ch][Ac] > PPG400+Na2SO4 > 
[P4444]Cl+K3C6H5O7/C6H5O7  > [Pi(444)l][Tos]+K3C6H5O7/C6H5O7 > 
PPG400+[Ch][DHCit] > > PEG3350+Dex500 > PPG400+(D)-sucrose > 
PEG400+PPG400 
In PPG400+Na2SO4 and PPG400+(D)-sucrose system, both enantiomers migrated 
preferentially to the PPG400 rich-phase as a result of the hydrophobic character of MA 
(translated by log Kow of 0.90).[192] Again, when ILs are used in polymer-based ABS, 
it is possible to observe an inversion of this behaviour. PPG400+[Ch][Ac] extracts both 
MA enantiomers to the IL-rich phase, which is more hydrophilic (E.E.R-MA of 99.45 ± 
1.32% and E.E.S-MA 93.75 ± 3.62%). This result indicates that specific interactions 
between the MA and [Ch][Ac] are taking place. 
All three IL-citrate buffer systems had values of E.E.MA above 80%, being the 
[N4444]Cl found to be the best IL to extract both enantiomers to the most hydrophobic 
IL-rich phase (E.E.R-MA of 95.84 ± 2.21% and E.E.S-MA of 91.18 ± 3.19%). When 
comparing [P4444]Cl and [N4444]Cl performance, the last is more hydrophilic[182,194] 
and the MA enantiomers will have more affinity to the [N4444]Cl. Once more, the MA 
extraction is driven by specific interactions established between the enantiomers and the 
IL in the system. 
In the case of polymer+polymer systems, as already described in the previous 
section, a delicate balance between the phases’ hydrophobicity-hydrophilicity must be 
achieved to tune the MA partition. 
It should be highlighted that the ABS formed by PPG400 and (D)-Sucrose without 
BSA yielded promising enantiomeric excesses of -12.3 ± 0.5%, due to the presence of a 
chiral selector also as phase former. This system will be object of further optimization 
in section 3.2.  
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Figure 14 - Extraction efficiencies of BSA (E.E.BSA, ), R-MA (E.E.R-MA, ) and S-MA (E.E.S-MA,) 
along with the enantiomeric excess (e.e., ●) obtained for the ABS studied. (a) partition studies in ABS 
with MA racemate and BSA performed separately. (b) enantioseparation studies in ABS with MA 
racemate and BSA performed together. 
 
PPG400+(D)-Sucrose is the ABS presenting the most significant difference in the 
migration tendencies for the protein and the enantiomers, seeming to be the best option 
for the development of novel chiral ABS containing BSA for MA enantioseparation. As 
for the previous studies with Cyt C, it is necessary to test the protein and the 
enantiomers simultaneously in the same systems to validate the real chiral resolution 
ability of these systems. The results obtained for the E.E. and e.e. in the BSA-based 
systems are shown in Figure 14b. It can be concluded that after introducing BSA in the 
ABS, there were some changes in the extraction and enantioseparation of MA 
enantiomers. Based on the molecular docking results, BSA should have more affinity to 
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the R-MA and this way, it will form a complex with this R-MA more easily, leaving S-
MA in the other phase. The ABS enantioseparation ability can be organized as follows 
(according the e.e. values): 
PPG400+(D)-sucrose (e.e. = -5.9 ± 0.5%) > [N4444]Cl+K3C6H5O7/C6H5O7 (e.e. = 5.5 
± 1.2%) > PPG400+[Ch][Ac] (e.e. = 3.8 ± 0.7%) > PPG400+[Ch][DHCit] (e.e. = -3.1 
± 0.6%) ~ PEG400+PPG400 (e.e. = -3.0 ± 0.6%)  > [Pi(444)l][Tos]+K3C6H5O7/C6H5O7 
(e.e. = 2.6 ± 1.6%) > [P4444]Cl+K3C6H5O7/C6H5O7  (e.e. = 2.1 ± 1.6%) = 
PPG400+Na2SO4 (e.e. = 2.1 ± 0.6%) > PEG3350+Dex500 (e.e. = -1.0 ± 0.1%) 
The best system for MA enantioseparation was the PPG400+(D)-sucrose+BSA. 
However, BSA decreased almost two times the enantiomeric excess. By introducing 
BSA, there was an increase in R-MA amount in the (D)-sucrose-rich phase, what is in 
accordance with the molecular docking results. Contrarily, in the ABS composed of 
[P4444]Cl and citrate buffer systems, the presence of BSA induced a slightly higher 
prevalence of S-MA in the IL-rich phase. This result may indicate that an appropriate 
choice of the phase formers is important for chiral recognition to occur. For instance, in 
this specific case, other interactions between the IL, the citrate salt, the protein and the 
MA may play a role. For the remaining systems, no significant effects were noticed. 
 
3.1.4. Can molecular docking be used to choose proteins as chiral selectors in ABS? - 
Cyt C versus BSA 
In order to infer on how molecular docking can be used to choose proteins as chiral 
selectors in ABS, it is important to compile all the results and compare the performance 
of distinct ABS containing Cyt C and BSA. For that, the ABS tested (PPG400+PEG400 
and PEG3350+Dex500) for both proteins were compared along with the ones yielding 
the highest enantiomeric excesses, according to Figure 15.  
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Figure 15 – Enantiomeric excesses of MA with BSA (e.e.BSA, ) and Cyt C (e.e.Cyt c, ) as chiral 
selectors in representative ABS. 
 
It can be concluded that the efficiency of a protein as chiral selector is dependent on 
the ABS phase formers and that distinct proteins will act differently in distinct systems. 
In the PPG400+PEG400 system, BSA and Cyt C perform similarly (-3.0 ± 0.6% versus 
1.9 ± 0.5%). Instead, when analysing the PEG3350+Dex500 system, Cyt C was shown 
to be a better chiral selector than BSA (6.3 ± 1.6% versus -1.0 ± 0.1%). The most 
significant values were achieved in PPG+[Ch][DHP]+Cyt C with e.e. of -9.0 ± 1.2% 
and PPG+(D)-sucrose+BSA with e.e. of -5.9 ± 0.5%. From the results gathered, it is 
possible to conclude that molecular docking does not seem to be the most adequate 
predicting tool for proteins as chiral selectors in ABS. Yet, further investigation on this 
aspect is needed. Molecular docking allows gaining insight into the interactions 
occurring between proteins and enantiomers and it can be used from a molecular 
perspective to explain the interactions occurring between BSA/Cyt C and the MA 
enantiomers. This bioinformatic tool is very useful for other types of studies, namely in 
drug design [149,154] and biocatalysis [146,147,152] (see Table 4). However, during 
this work, it was shown that the enantioseparation in ABS is largely influenced by the 
phase formers. This aspect can be identified as the main factor limiting the success of 
using molecular docking as predicting tool, since AutoDock Vina can only visualize the 
interactions between the protein and the small molecule, dismissing the interactions 
from surrounding molecules. In Figure 16, it is shown the workflow for the dissertation. 
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During the tests, the polymer-sugar system with the best result to enantioseparation 
without protein, suggested another path to explore: a phase former with the capacity of 
chiral selector. 
 
Figure 16 – Scheme of work-flow to explain the used of ABS with (D)-sucrose. 
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3.2. Sucrose as chiral selector and phase former in ABS for MA 
enantioseparation  
As mentioned above, PPG400+(D)-sucrose system revealed enhanced 
enantioseparation ability when compared to the poor performance of proteins. Under 
this scenario, the use of sucrose as phase former and chiral selector was objective of 
further investigation. Sucrose is a naturally occurring carbohydrate, consisting of a 
disaccharide of glucose and fructose. The potential of sucrose as chiral selector is well-
known, for instance in the determination of the enantiomeric composition of a D-Phe/L-
Phe mixture by UV-Vis spectroscopy.[161] The potential of sucrose as ABS phase 
former is recognized, when combined with different ILs[68,194] or polymers.[168]  
Two distinct types of ABS were included in this study: PPG400+(D)-sucrose and 
[C4mim][CF3SO3]+(D)-sucrose. A common extraction point selected from the phase 
diagrams reported in literature [68,167] was adopted for these two systems, allowing the 
direct comparison (40 wt% (D)-sucrose + 20 wt% PPG400/[C4mim][CF3SO3]). The 
extraction efficiencies and enantiomeric excesses toward the sugar-enriched phase are 
presented in Figure 17 and all detailed data is presented in Appendix C. When 
comparing different systems, the extraction efficiencies and enantiomeric excesses for 
S-MA are similar, suggesting that (D)-sucrose is the phase former controlling the MA 
migration and both PPG400 and [C4mim][CF3SO3] play a minor role. When compared 
to the systems including proteins, these systems show improved performance and lower 
operational complexity, once (D)-sucrose encompasses two functions (phase former and 
chiral selector). 
 
 
Figure 17 - Extraction efficiencies of R-MA (E.E.R-MA ) and S-MA (E.E.S-MA,) along with the 
enantiomeric excess (e.e., ●) obtained for the (D)-sucrose-based ABS studied. 
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Given the promising results obtained and to maximize the enantioseparations 
afforded by these systems, the ABS composition was optimized. For that, distinct 
mixture points were selected at the biphasic region of the phase diagram (26 wt% 
PPG400+26 wt% (D)-sucrose, 20 wt% PPG400 + 40 wt% (D)-sucrose and 30 wt% 
PPG400 + 30wt% (D)-sucrose). The respective results are depicted in Figure 18 and 
indicate a considerable influence of the extraction point on both the MA extraction 
efficiency and enantiomeric excess. Extraction points located closer to the binodal curve 
yield phases with higher water contents; those located far induce the formation of 
phases richer in either the polymer (top) or sucrose (bottom). It can be concluded that 
lower water contents prompt the enantioseparations, although slightly minimizing the 
extraction efficiencies. This result indicates that the extraction of MA in PPG400/(D)-
sucrose system is driven by the hydrophobicity/hydrophilicity of the phases. The same 
findings were provided by Zafarani-Moattar et al. for paracetamol extraction in 
polymer/ILs systems [196]. Regarding enantioseparation, as soon as the (D)-sucrose 
becomes richer in the sugar, more interactions will occur between S-MA and (D)-
sucrose, increasing the enantiomeric excess up to 2-fold. 
  
Figure 18 – Evaluation of the mixture point influence on the extraction efficiencies of R-MA (E.E.R-MA ) 
and S-MA (E.E.S-MA,) and the enantiomeric excess (e.e., ●) in the (D)-sucrose-based ABS: phase 
diagram data (♦); mixture points at 26 wt%+26 wt% (●),40 wt%+20 wt% () and 30 wt%+30 wt% of 
(D)-sucrose and PPG400, respectively (▲). 
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4.1. Conclusions 
In this work, different approaches to separate MA enantiomers were attempted. One 
was based on the use of proteins as chiral selectors in ABS and the other was related 
with the use of D-sucrose as both phase former and chiral selector in ABS. 
A bioinformatic tool, AutoDock Vina, was used to predict the interactions between 
several proteins and MA enantiomers. With this computational screening, it was 
expected to select ideal proteins as chiral selectors in ABS, avoiding experimental trial-
error screenings and thus saving money and time. The role of proteins as chiral selectors 
in ABS was shown to be dependent on both the protein used (Cyt C or BSA) and on the 
type of phase formers selected (polymer+salt, polymer+polymer, polymer+IL, IL+salt 
and polymer+sugar). The best enantioseparation results were obtained for 
PPG400+[Ch][DHP]+Cyt C (e.e. = -9.0 ± 1.2%) and for PPG400+(D)-sucrose+BSA 
(e.e. = -5.9 ± 0.5%). Although the obtained enantioseparation abilities are somehow 
limited, a balance of interactions occurring between the protein, enantiomers and phase 
formers influences both the partition and enantioseparation within the ABS tested. 
However, the molecular docking screening failed to fit the experimental results obtained 
likely due to the effect that the phase formers seem to exert. Still, AutoDock Vina can 
be useful to understand the interactions in the complexes protein-enantiomer formed 
and further studies may be valuable. 
During this thesis, the most performant ABS achieved was composed of PPG400 
and (D)-sucrose system. After an optimization of the component paired with (D)-
sucrose (PPG400 or [C4mim][CF3SO3]) and the mixture point utilized, a maximum e.e. 
of -12.3  ± 0.5% was obtained. Lower water contents in the ABS were shown to favour 
enantiorecognition. 
 
4.2. Future Work 
Further optimization of the ABS here screened must be performed. Most 
importantly those composed of (D)-sucrose but also the most promising protein-based 
ABS, should be studied regarding extraction points, protein type/concentration, 
enantiomers concentration and pH. Moreover, an extended panoply of ABS and proteins 
should be investigated to confirm whether molecular docking is adequate or not. 
The system composed of PPG400+(D)-sucrose, being of simpler nature and 
composed of cheap chemicals, could easily be operated in continuous mode (using 
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centrifugal partition chromatography or counter-current chromatography), which could 
enable full separation of the enantiomers. 
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A. Calibration curves of R- and S-mandelic acid 
 
 
Figure A.1 - Calibration curves of R-MA (●) and S-MA (●), respectively. 
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B. Molecular docking 
 
Table B.1 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for amylase- MA enantiomers. 
α-amylase 
(PDB: 1UA7) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of 
interaction 
From To 
Distance  
(Å) 
R-MA -5.0 
Glutamate208 
Hydrogen bond 
R-MA Glu208 2.57 
Aspartate269 
R-MA Asp 269 1.79 
Electrostatic Asp269 R-MA 3.71 
Tyrosine62 Hydrophobic Tyr62  R-MA 5.18 
S-MA -4.8 
Triptophan58 
Hydrogen bond 
Trp58 S-MA 3.18 
Aspartate274 
S-MA Asp274 2.95 
S-MA Asp274 2.98 
Tyrosine59 Hydrophobic Tyr59 S-MA 4.12 
 
Table B.2 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for Bromelain- MA enantiomers. 
Bromelain 
(PDB:1W0Q) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of 
interaction 
From To Distance (Å) 
R-MA -5.4 
Lysine18 
Hydrogen bond 
Lys18 R-MA 2.62 
Phenyl29 R-MA Phe29 2.29 
Ser16 R-MA Ser16 3.01 
Valine17 Val17 R-MA 2.85 
Alanine33 Hydrophobic R-MA Ala33 3.85 
S-MA -5.4 
Cystosine26 
Hydrogen Bond 
S-MA Cys26 2.54 
Threonine161 S-MA Thr161 2.50 
Alanine30 Ala30 S-MA 2.40 
Lysine18 
Hydrophobic 
S-MA Lys18 5.34 
Alanine33 S-MA Ala33 4.94 
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Table B.3 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for GFP- MA enantiomers. 
Green 
fluorescent 
protein 
(PDB:4KW4) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of 
interaction 
From To 
Distance 
(Å) 
R-MA -5.1 
Serine28 
Hydrogen bond 
Ser28 R-MA 2.35 
Aspartate19 
R-MA Asp19 2.70 
Electrostatic Asp19 R-MA 4.08 
Arginine122 Hydrophobic R-MA Arg122 4.54 
S-MA -4.7 
Histidine139 
Hydrogen bond 
His139 S-MA 3.02 
Valine55 S-MA Val55 2.22 
Aspartate216 S-MA Asp216 3.10 
Tyrosine143 Hydrophobic Tyr143 S-MA 5.26 
 
Table B.4 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for Hexokinase II- MA enantiomers. 
Hexokinase PII 
(PDB:1IG8) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of 
interaction 
From To 
Distance  
(Å) 
R-MA -4.4 
Leucine387 
Hydrogen bond 
R-MA Leu387 2.11 
Threonine35 R-MA Thr35 2.09 
Arginine394 Arg394 R-MA 3.58 
Alanine390 Hydrophobic R-MA Ala390 3.47 
S-MA -4.6 
Threonine108 
Hydrogen bond 
Thr108 S-MA 2.91 
Aspartate106 S-MA Asp106 2.59 
Threonine108 S-MA Thr108 2.11 
Lysine98 Hydrophobic S-MA Lys98 3.79 
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Table B.5 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for HSA- MA enantiomers. 
Human Serum 
Albumin 
(PDB:1E7I) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of 
interaction 
From To 
Distance  
(Å) 
R-MA -5.6 
Valine418 
Hydrophobic 
Val418 R-MA 3.95 
Val418 R-MA 3.80 
Valine415 R-MA Val415 5.11 
Valine426 R-MA Val426 5.41 
Leucine460 
R-MA Leu460 4.47 
Hydrogen 
R-MA Leu460 2.92 
R-MA Leu460 2.99 
S-MA -5.6 
Valine23 
Hydrophobic 
S-MA Val23 5.44 
Leucine66 S-MA Leu66 5.06 
 
Table B.6 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for Lysozyme- MA enantiomers. 
Lysozyme 
(PDB:4YM8) 
Affinity 
(kcal.mol-1) 
Interacting 
nucleic acids 
Type of 
interaction 
From To 
Distance  
(Å) 
R-MA -4.4 
Asparagine59 
Hydrogen bond 
Asn59 R-MA 3.11 
Tryptophan63 Trp63 R-MA 2.95 
Alanine107 R-MA Ala107 1.97 
Aspartate52 Electrostatic Asp52 R-MA 4.71 
S-MA -4.4 
Aspartate101 
Hydrogen bond S-MA Asp101 1.95 
Electrostatic Asp101 S-MA 4.46 
Tryptophan62 Hydrophobic 
Trp62 S-MA 3.88 
Trp62 S-MA 3.75 
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Table B.7 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for Laccase- MA enantiomers. 
Laccase 
(PDB:1KYA) 
Affinity 
(kcal.mol-1) 
Interacting 
nucleic acids 
Type of 
interaction 
From To 
Distance  
(Å) 
R-MA -5.0 
Phenylalanine162 
Hydrophobic 
Phe162 R-MA 4.22 
Proline391 R-MA Pro391 4.96 
Histidine458 Hydrogen bond R-MA His458 2.28 
S-MA -5.0 
Phenylalanine162 
Hydrophobic 
Phe162 S-MA 4.26 
Proline391 S-MA Pro391 4.74 
Glycine392 Hydrogen bond Gly392 S-MA 3.14 
 
Table B.8 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for Ovalbumin- MA enantiomers. 
Ovalbumin 
(PDB:1OVA) 
Affinity 
(kcal.mol-1) 
Interacting 
nucleic acids 
Type of 
interaction 
From To 
Distance  
(Å) 
R-MA -4.3 
Lysine292 
Hydrogen bond 
Lys292 R-MA 3.17 
Arginine290 R-MA Arg290 2.78 
Proline391 R-MA Pro391 2.23 
Lysine292 Electrostatic Lys292 R-MA 4.83 
Arginine290 
Hydrophobic 
R-MA Arg290 4.15 
Lysine292 R-MA Lys292 5.22 
S-MA -4.6 
Glutamine219 
Hydrogen bond 
Gln219 S-MA 3.01 
Gln219 S-MA 3.25 
Arginine290 S-MA Arg290 2.45 
Proline391 S-MA Pro391 2.49 
Arginine290 
Hydrophobic 
S-MA Arg290 4.13 
Lysine292 S-MA Lys292 5.48 
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Table B.9 - Docking affinity energy and interacting amino acids predicted by AutoDock Vina for Phycoerythrin- MA enantiomers. 
Phycoerythrin 
(PDB:1EYX) 
Affinity 
(kcal.mol-1) 
Interacting amino 
acids 
Type of 
interaction 
From To 
Distance  
(Å) 
R-MA -4.3 
Cysteine158 
Hydrogen bond 
Cys158 R-MA 3.67 
Aspartate39 R-MA Asp39 3.61 
Lysine36 
Hydrophobic 
R-MA Lys36 3.88 
Ileucine154 R-MA Ile154 5.22 
S-MA -4.3 
Serine102 
Hydrogen bond 
Ser102 S-MA 3.25 
Ser102 S-MA 2.83 
Aspartate101 
S-MA Asp101 2.87 
S-MA Asp101 2.39 
Tyrosine168 
Tyr168 S-MA 4.08 
Hydrophobic Tyr168 S-MA 4.81 
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Figure B.1 - The Amylase docking pose with the lowest absolute value of affinity (kcal.mol-1) for 
Amylase with (a) R-MA and (b) S-MA ((----) hydrogen bond, (----) π-anion bond and (----) π-alkyl 
bond. 
 
Figure B.2- The Bromelain docking pose with the lowest absolute value of affinity (kcal.mol-1) for 
Bromelain with (a) R-MA and (b) S-MA ((----) hydrogen bond and (----) π-alkyl.  
 
Figure B.3 - The GFP docking pose with the lowest absolute value of affinity (kcal.mol-1) for GFP with 
(a)  R-MA and (b) S-MA ((----) hydrogen bond, (----) π-anion bond, (----) π-alkyl bond and (----) π 
– π bond).  
 
Figure B.4 - The Hexokinase PII docking pose with the lowest absolute value of affinity (kcal.mol-1)for 
Hexokinase PII with (a) R-MA and (b) S-MA ((----) hydrogen bond, (----) π-alkyl bond and (----) C-
H bond). 
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Figure B.5 - The HSA docking pose with the lowest absolute value of affinity (kcal.mol-1) for HSA with 
(a) R-MA and (b) S-MA ((----) hydrogen bond, (----) π-σ bond and (----) π-alkyl bond. 
 
Figure B.6 - The Lysozyme docking pose with the lowest absolute value of affinity (kcal.mol-1) for 
Lysozyme with (a) R-MA and (b) S-MA ((----) hydrogen bond, (----) π-σ bond, (----) π-anion bond. 
 
Figure B.7 - The Laccase docking pose with the lowest absolute value of affinity (kcal.mol-1) for Laccase 
with (a) R-MA and (b) S-MA ((----) hydrogen bond, (----) π-alkyl bond and (----) π – π bond).  
 
Figure B.8 - The Ovalbumin docking pose with the lowest absolute value of affinity (kcal.mol-1) for 
Ovalbumin with (a) R-MA and (b) S-MA ((----) hydrogen bond, (----) π-anion bond and (----) π-alkyl 
bond.  
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Figure B.9 - The Phycoerythrin docking pose with the lowest absolute value of affinity (kcal.mol-1) for 
Phycoerythrin with (a) R-MA and (b) S-MA ((----) hydrogen bond, (----) π-alkyl bond and (----) π – 
π bond).  
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C. Extraction efficiency and enantiomeric excess data 
 
Table C.1 - Extraction efficiency of Cyt C (E.E.Cyt C), extraction efficiency and enantiomeric excess of MA in the presence and absence of Cyt C in the ABS studied.  
Phase formers 
Mixture 
composition  
MA (without Cyt C) Cyt C MA (with Cyt C) 
1 2 
1 / 
(wt%) 
2 / 
(wt%) 
E.E.R-MA± σ / 
(%) 
E.E.S-MA± / σ 
(%) 
e.e. ± σ / 
(%) 
E.E.cyt C± σ 
/ (%) 
E.E.R-MA± σ 
/ (%) 
E.E.S-MA± σ 
/ (%) 
e.e. ± σ / 
(%) 
PEG400 Na2SO4 22 12 2.94 ± 0.02 0.99 ± 0.13 1.2 ± 0.4 91.66 ± 0.22 2.76 ± 0.59 0.20 ± 0.80 1.2 ± 0.4 
PPG400 [Ch][DHP] 30 30 43.44 ± 0.39 50.26 ± 0.91 -7.6 ± 0.5 86.13 ± 2.01 40.68 ± 3.14 
48.69 ± 
1.55 
-9.0 ± 1.2 
PEG400 PPG400 25 35 59.44 ± 1.62 73.82 ± 1.68 -9.8 ± 0.5 93.99 ± 0.50 64.95 ± 1.34 
63.54 ± 
1.61 
1.9 ± 0.9 
[C4mim]Cl C6H5K3O7 22 33 53.77 ± 4.56 55.05 ± 3.36 -1.3 ± 1.3 89.44 ± 0.75 91.68 ± 4.60 
83.16 ± 
3.07 
5.0 ± 1.0 
PEG3350 Dex500 5 15 40.69 ± 2.02 46.40 ± 1.56 -4.6 ± 0.9 70.74 ± 1.24 56.49 ± 3.17 
49.84 ± 
1.42 
6.3 ± 1.6 
 
Table C.2 - Extraction efficiency of BSA (E.E.BSA), extraction efficiency and enantiomeric excess of MA in the presence and absence of BSA in the ABS studied. Literature 
data extracted from Quental et al.a, Taha et al.b and Pereira et al.c 
Phase formers 
Mixture 
composition  
MA (without BSA) BSA MA (with BSA) 
1 2 
1 / 
(wt%) 
2 / 
(wt%) 
E.E.R-MA± 
σ / (%) 
E.E.S-MA± σ 
/ (%) 
e.e. ± σ / 
(%) 
E.E.BSA± σ 
/ (%) 
E.E.R-MA± 
σ / (%) 
E.E.S-MA± σ 
/ (%) 
e.e. ± σ / 
(%) 
PPG400 
[Ch][Ac] 30 30 
99.45 ± 
1.32 
93.76 ± 3.62 3.2 ± 1.5 100a 
87.80 ± 
0.39 
81.64 ± 0.74 3.8 ± 0.7 
[Ch][DHCit] 30 30 
47.24 ± 
1.49 
52.08 ± 2.93 -4.6 ± 1.5 100a 
46.42 ± 
3.06 
49.65 ± 3.91 -3.1 ± 0.6 
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(D)-sucrose 30 30 
26.47 ± 
1.29 
34.00 ± 1.45 
-12.3 ± 
0.5 
100b 
30.01 ± 
0.18 
33.68 ± 0.11 -5.9 ± 0.5 
Na2SO4 22 12 
97.43 ± 
2.42 
86.90 ± 3.86 6.1 ± 1.9 
55.00 ± 
2.55 
72.30 ± 
1.31 
69.71 ± 1.73 2.1 ± 0.6 
PEG400 35 25 
59.44 ± 
1.62 
73.82 ± 1.68 -9.8 ± 0.5 90.36 ± 0.5 
60.78 ± 
2.83 
64.71 ± 0.51 -3.0 ± 0.6 
PEG3350 Dex500 5 15 
40.69 ± 
2.02 
46.40 ± 1.56 -4.6 ± 0.9 
89.43 ± 
1.24 
74.99 ± 
1.10 
76.29 ± 1.21 -1.0 ± 0.1 
[Pi(444)1][Tos] 
K3C6H5O7/ 
C6H8O7 
30 15 
86.10 ± 
3.30 
81.74 ± 1.96 2.4 ± 0.8 100c 
78.10 ± 
1.97 
71.44 ± 2.09 2.6 ± 1.6 
[P4444]Cl 30 15 
89.00 ± 
1.21 
79.30 ± 0.85 5.6 ± 0.9 100c 
83.07 ± 
0.53 
88.18 ± 1.47 2.1 ± 1.6 
[N4444]Cl 30 15 
95.84 ± 
2.21 
91.18 ± 3.19 2.3 ± 0.8 100c 
96.89 ± 
2.31 
86.56 ± 2.28 5.5 ± 1.2 
 
Table C.3 - Extraction efficiency and enantiomeric excess of MA in the different systems with (D)-sucrose.  
Phase formers Mixture composition (wt%)  
1 2 1 / (wt%) 2 / (wt%) E.E.R-MA± σ / (%) E.E.S-MA± σ / (%) e.e. ± σ / (%) 
PPG400 
(D)-Sucrose 
26 26 41.42 ± 0.91 47.57 ± 0.74 -6.7 ± 1.7 
20 40 36.46 ± 0.69 45.30 ± 1.72 -10.6 ± 1.7 
30 30 26.47 ± 1.29 34.00 ± 1.45 -12.3 ± 0.5 
[C4mim][CF3SO3] 20 40 38.89 ± 1.42 47.82 ± 1.27 -10.6 ± 1.3 
 
